Trial Outcomes & Findings for A Study to Assess Frailty of Subjects During ZOSTER-006 and ZOSTER-022 (NCT NCT03563183)
NCT ID: NCT03563183
Last Updated: 2020-04-30
Results Overview
Frailty status was measured in relation to the accumulation of deficits using a Frailty Index (FI) adapted from the model proposed by Mitnitski et al. \[Mitnitski, 2001\]. The different aspects of frailty composing the FI were assessed through the medical history and components of the Short Form 36 Questionnaire (SF-36) and EuroQol (EQ)-5D questionnaires recorded pre-vaccination Dose 1 (in the study ZOSTER-006\[NCT01165177\] and ZOSTER-022\[NCT01165229\]). If the FI was less than or equal to 0.08, the subject was classified as Non-Frail. If the score was greater than 0.08 but less than or equal to 0.25, the subject was classified as pre-frail. If the score was greater than 0.25, the subject was classified as Frail. Subjects without a FI score were classified as unknown.
Recruitment status
COMPLETED
Target enrollment
26976 participants
Primary outcome timeframe
At Baseline (Month 0)
Results posted on
2020-04-30
Participant Flow
Of the 29305 subjects in the Total Vaccinated cohort (TVC) of study ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229), 2329 subjects were excluded as they belonged to centers not participating in the current study Zoster-064(Z-064). Thus, 26976 subjects were eligible for Inclusion in the Z-064 TVC.
Participant milestones
| Measure |
Overall Group
Adults aged ≥50 years of age in the Zoster-064 TVC who received herpes zoster subunit (HZ/su) vaccine or Placebo in Zoster-006/022 study
|
|---|---|
|
Overall Study
STARTED
|
26976
|
|
Overall Study
COMPLETED
|
26976
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
A Study to Assess Frailty of Subjects During ZOSTER-006 and ZOSTER-022
Baseline characteristics by cohort
| Measure |
Overall Group
n=26976 Participants
Adults aged ≥50 years of age in the Zoster-064 TVC who received herpes zoster subunit (HZ/su) vaccine or Placebo in Zoster-006/022 study
|
|---|---|
|
Age, Continuous
|
68.8 Years
STANDARD_DEVIATION 9.8 • n=5 Participants
|
|
Sex: Female, Male
Female
|
15685 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
11291 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
African Heritage / African American
|
347 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
American Indian or Alaskan Native
|
20 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Asian - Central/South Asian Heritage
|
13 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Asian - East Asian Heritage
|
4090 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Asian - Japanese Heritage
|
901 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Asian - South East Asian Heritage
|
38 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Native Hawaiian or Other Pacific Islander
|
6 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
White - Arabic / North African Heritage
|
161 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
White - Caucasian / European Heritage
|
20112 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Other
|
1288 Participants
n=5 Participants
|
PRIMARY outcome
Timeframe: At Baseline (Month 0)Population: Analysis was performed on all subjects included in the Total Vaccinated Cohort (TVC) of Zoster-064
Frailty status was measured in relation to the accumulation of deficits using a Frailty Index (FI) adapted from the model proposed by Mitnitski et al. \[Mitnitski, 2001\]. The different aspects of frailty composing the FI were assessed through the medical history and components of the Short Form 36 Questionnaire (SF-36) and EuroQol (EQ)-5D questionnaires recorded pre-vaccination Dose 1 (in the study ZOSTER-006\[NCT01165177\] and ZOSTER-022\[NCT01165229\]). If the FI was less than or equal to 0.08, the subject was classified as Non-Frail. If the score was greater than 0.08 but less than or equal to 0.25, the subject was classified as pre-frail. If the score was greater than 0.25, the subject was classified as Frail. Subjects without a FI score were classified as unknown.
Outcome measures
| Measure |
Overall Group
n=26976 Participants
Adults aged ≥50 years of age in the Zoster-064 TVC who received herpes zoster subunit (HZ/su) vaccine or Placebo in Zoster-006/022 study
|
Non-Frail-Placebo
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as non-frail.
|
Pre-Frail-HZ/su
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were categorized as pre-frail.
|
Pre-Frail-Placebo
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as pre-frail.
|
Frail-HZ/su
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were categorized as frail.
|
Frail-Placebo
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as frail.
|
Unknown-HZ/su
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were not assigned a frailty category.
|
Unknown-Placebo
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were not assigned a frailty category.
|
|---|---|---|---|---|---|---|---|---|
|
Number of Subjects by Frailty Status, at Baseline
Non-Frail
|
11518 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Subjects by Frailty Status, at Baseline
Pre-Frail
|
12290 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Subjects by Frailty Status, at Baseline
Frail
|
3037 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Subjects by Frailty Status, at Baseline
Unknown
|
131 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: At Month 0, 14, 26 and 38Population: Analysis was performed on all subjects included in the Total Vaccinated Cohort (TVC) of Zoster-064
The mean and standard deviation of the SF-36 Questionnaire scale scores are presented for each time point. The SF-36 is a multi-purpose health survey with 36 questions underlying the construction of 8 scales \[Ware, 2001\]: Physical Functioning (PF), Role Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role Emotional (RE) and Mental Health (MH). All but one of the 36 items (self-reported health transition) are used to score the eight SF-36 scales. Each item is used in scoring only one scale. Scale scores are constructed following the summated ratings and standardized SF-36 scoring algorithms. The SF-36 scores range from 0 to 100, with high scores indicating high levels of functioning/quality of life.
Outcome measures
| Measure |
Overall Group
n=26976 Participants
Adults aged ≥50 years of age in the Zoster-064 TVC who received herpes zoster subunit (HZ/su) vaccine or Placebo in Zoster-006/022 study
|
Non-Frail-Placebo
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as non-frail.
|
Pre-Frail-HZ/su
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were categorized as pre-frail.
|
Pre-Frail-Placebo
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as pre-frail.
|
Frail-HZ/su
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were categorized as frail.
|
Frail-Placebo
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as frail.
|
Unknown-HZ/su
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were not assigned a frailty category.
|
Unknown-Placebo
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were not assigned a frailty category.
|
|---|---|---|---|---|---|---|---|---|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 PF (Finland)
|
84.66 Scale score
Standard Deviation 17.428
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 RP (Finland)
|
86.35 Scale score
Standard Deviation 20.421
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 RE (Australia)
|
86.07 Scale score
Standard Deviation 22.532
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 MH (Czechia)
|
72.78 Scale score
Standard Deviation 16.972
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 SF (Estonia)
|
91.78 Scale score
Standard Deviation 15.802
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 RE (Estonia)
|
91.69 Scale score
Standard Deviation 16.141
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 MH (Estonia)
|
80.04 Scale score
Standard Deviation 15.286
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 PF (Estonia)
|
75.97 Scale score
Standard Deviation 23.487
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 RP (Estonia)
|
77.40 Scale score
Standard Deviation 25.983
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 BP (Estonia)
|
71.82 Scale score
Standard Deviation 25.076
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 GH (Estonia)
|
57.17 Scale score
Standard Deviation 18.677
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 VT (Estonia)
|
70.91 Scale score
Standard Deviation 18.447
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 SF (Estonia)
|
91.00 Scale score
Standard Deviation 16.763
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 MH (Estonia)
|
79.17 Scale score
Standard Deviation 16.572
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 PF (Estonia)
|
65.95 Scale score
Standard Deviation 26.066
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 RP (Estonia)
|
67.55 Scale score
Standard Deviation 27.894
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 BP (Estonia)
|
66.18 Scale score
Standard Deviation 25.194
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 GH (Estonia)
|
52.15 Scale score
Standard Deviation 18.654
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 VT (Estonia)
|
64.66 Scale score
Standard Deviation 19.248
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 SF (Estonia)
|
84.31 Scale score
Standard Deviation 21.233
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 BP (Estonia)
|
59.45 Scale score
Standard Deviation 23.335
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 GH (Estonia)
|
48.53 Scale score
Standard Deviation 17.687
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 VT (Estonia)
|
61.79 Scale score
Standard Deviation 18.816
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 SF (Estonia)
|
81.45 Scale score
Standard Deviation 21.281
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 RE (Estonia)
|
70.20 Scale score
Standard Deviation 26.084
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 MH (Estonia)
|
73.08 Scale score
Standard Deviation 17.225
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 BP (Finland)
|
78.31 Scale score
Standard Deviation 20.019
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 GH (Finland)
|
72.29 Scale score
Standard Deviation 16.823
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 VT (Finland)
|
74.18 Scale score
Standard Deviation 16.187
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 SF (Finland)
|
94.09 Scale score
Standard Deviation 13.016
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 RE (Finland)
|
90.11 Scale score
Standard Deviation 17.475
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 MH (Finland)
|
86.54 Scale score
Standard Deviation 12.558
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 PF (Finland)
|
81.56 Scale score
Standard Deviation 20.057
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 RP (Finland)
|
82.89 Scale score
Standard Deviation 23.143
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 BP (Finland)
|
73.76 Scale score
Standard Deviation 22.297
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 GH (Finland)
|
69.35 Scale score
Standard Deviation 18.022
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 SF (Finland)
|
91.98 Scale score
Standard Deviation 16.306
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 RE (Finland)
|
87.91 Scale score
Standard Deviation 19.929
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 PF (Finland)
|
80.68 Scale score
Standard Deviation 20.609
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 PF (Finland)
|
79.14 Scale score
Standard Deviation 21.864
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 RP (Finland)
|
79.86 Scale score
Standard Deviation 24.883
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 VT (Finland)
|
69.30 Scale score
Standard Deviation 19.226
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 SF (Finland)
|
90.65 Scale score
Standard Deviation 17.284
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 BP (Germany)
|
71.81 Scale score
Standard Deviation 27.520
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 PF (Australia)
|
75.50 Scale score
Standard Deviation 23.366
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 RP (Australia)
|
80.43 Scale score
Standard Deviation 24.521
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 BP (Australia)
|
74.49 Scale score
Standard Deviation 23.545
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 GH (Australia)
|
76.15 Scale score
Standard Deviation 17.016
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 VT (Australia)
|
67.58 Scale score
Standard Deviation 18.344
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 SF (Australia)
|
91.11 Scale score
Standard Deviation 16.485
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 RE (Australia)
|
88.76 Scale score
Standard Deviation 19.879
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 MH (Australia)
|
84.12 Scale score
Standard Deviation 13.975
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 PF (Australia)
|
72.78 Scale score
Standard Deviation 24.472
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 RP (Australia)
|
76.39 Scale score
Standard Deviation 26.339
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 BP (Australia)
|
70.46 Scale score
Standard Deviation 24.483
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 GH (Australia)
|
71.73 Scale score
Standard Deviation 18.227
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 VT (Australia)
|
64.26 Scale score
Standard Deviation 21.926
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 SF (Australia)
|
85.92 Scale score
Standard Deviation 23.581
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 MH (Australia)
|
82.18 Scale score
Standard Deviation 16.909
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 PF (Australia)
|
73.01 Scale score
Standard Deviation 24.468
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 RP (Australia)
|
76.12 Scale score
Standard Deviation 25.386
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 BP (Australia)
|
70.10 Scale score
Standard Deviation 24.188
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 GH (Australia)
|
70.38 Scale score
Standard Deviation 18.815
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 VT (Australia)
|
62.18 Scale score
Standard Deviation 21.385
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 SF (Australia)
|
87.26 Scale score
Standard Deviation 21.499
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 RE (Australia)
|
85.84 Scale score
Standard Deviation 22.472
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 MH (Australia)
|
81.22 Scale score
Standard Deviation 17.017
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 PF (Australia)
|
71.83 Scale score
Standard Deviation 25.972
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 RP (Australia)
|
74.16 Scale score
Standard Deviation 27.235
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 BP (Australia)
|
70.06 Scale score
Standard Deviation 23.919
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 GH (Australia)
|
70.79 Scale score
Standard Deviation 19.777
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 VT (Australia)
|
63.68 Scale score
Standard Deviation 21.220
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 SF (Australia)
|
86.14 Scale score
Standard Deviation 21.822
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 RE (Australia)
|
85.57 Scale score
Standard Deviation 22.371
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 MH (Australia)
|
82.26 Scale score
Standard Deviation 15.807
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 PF (Brazil)
|
74.90 Scale score
Standard Deviation 23.505
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 RP (Brazil)
|
81.74 Scale score
Standard Deviation 24.185
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 BP (Brazil)
|
69.57 Scale score
Standard Deviation 26.057
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 GH (Brazil)
|
76.25 Scale score
Standard Deviation 18.983
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 VT (Brazil)
|
72.53 Scale score
Standard Deviation 20.835
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 SF (Brazil)
|
84.33 Scale score
Standard Deviation 21.505
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 RE (Brazil)
|
83.48 Scale score
Standard Deviation 22.963
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 MH (Brazil)
|
79.13 Scale score
Standard Deviation 19.192
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 PF (Brazil)
|
72.60 Scale score
Standard Deviation 23.984
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 RP (Brazil)
|
79.01 Scale score
Standard Deviation 26.311
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 BP (Brazil)
|
68.14 Scale score
Standard Deviation 26.068
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 GH (Brazil)
|
74.10 Scale score
Standard Deviation 19.110
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 VT (Brazil)
|
71.70 Scale score
Standard Deviation 21.709
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 SF (Brazil)
|
83.22 Scale score
Standard Deviation 23.396
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 RE (Brazil)
|
84.07 Scale score
Standard Deviation 23.233
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 MH (Brazil)
|
78.24 Scale score
Standard Deviation 20.318
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 PF (Brazil)
|
73.28 Scale score
Standard Deviation 24.185
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 RP (Brazil)
|
81.85 Scale score
Standard Deviation 25.360
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 BP (Brazil)
|
69.69 Scale score
Standard Deviation 26.737
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 GH (Brazil)
|
74.96 Scale score
Standard Deviation 19.553
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 VT (Brazil)
|
71.92 Scale score
Standard Deviation 21.804
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 SF (Brazil)
|
85.78 Scale score
Standard Deviation 22.726
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 RE (Brazil)
|
85.78 Scale score
Standard Deviation 21.389
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 MH (Brazil)
|
79.57 Scale score
Standard Deviation 19.974
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 PF (Brazil)
|
71.21 Scale score
Standard Deviation 25.322
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 RP (Brazil)
|
80.08 Scale score
Standard Deviation 26.268
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 BP (Brazil)
|
68.77 Scale score
Standard Deviation 26.803
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 GH (Brazil)
|
73.18 Scale score
Standard Deviation 20.140
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 VT (Brazil)
|
70.61 Scale score
Standard Deviation 20.626
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 SF (Brazil)
|
83.81 Scale score
Standard Deviation 22.055
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 RE (Brazil)
|
84.27 Scale score
Standard Deviation 22.853
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 MH (Brazil)
|
77.96 Scale score
Standard Deviation 20.046
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 PF (Canada)
|
76.09 Scale score
Standard Deviation 23.037
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 RP (Canada)
|
80.66 Scale score
Standard Deviation 23.449
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 BP (Canada)
|
75.10 Scale score
Standard Deviation 23.078
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 GH (Canada)
|
78.52 Scale score
Standard Deviation 16.334
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 VT (Canada)
|
71.69 Scale score
Standard Deviation 16.811
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 SF (Canada)
|
91.16 Scale score
Standard Deviation 16.701
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 RE (Canada)
|
88.48 Scale score
Standard Deviation 19.363
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 MH (Canada)
|
83.37 Scale score
Standard Deviation 14.410
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 PF (Canada)
|
73.53 Scale score
Standard Deviation 25.628
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 RP (Canada)
|
77.13 Scale score
Standard Deviation 25.882
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 BP (Canada)
|
72.65 Scale score
Standard Deviation 24.338
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 GH (Canada)
|
75.14 Scale score
Standard Deviation 18.174
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 VT (Canada)
|
68.40 Scale score
Standard Deviation 19.040
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 SF (Canada)
|
87.72 Scale score
Standard Deviation 19.983
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 RE (Canada)
|
85.55 Scale score
Standard Deviation 22.416
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 MH (Canada)
|
81.57 Scale score
Standard Deviation 15.655
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 PF (Canada)
|
72.97 Scale score
Standard Deviation 25.430
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 RP (Canada)
|
76.35 Scale score
Standard Deviation 25.745
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 BP (Canada)
|
71.62 Scale score
Standard Deviation 23.950
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 GH (Canada)
|
74.86 Scale score
Standard Deviation 18.540
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 VT (Canada)
|
67.67 Scale score
Standard Deviation 19.021
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 SF (Canada)
|
87.83 Scale score
Standard Deviation 19.836
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 RE (Canada)
|
85.08 Scale score
Standard Deviation 22.514
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 MH (Canada)
|
81.76 Scale score
Standard Deviation 15.452
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 PF (Canada)
|
71.54 Scale score
Standard Deviation 25.455
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 RP (Canada)
|
75.04 Scale score
Standard Deviation 26.340
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 BP (Canada)
|
69.93 Scale score
Standard Deviation 24.498
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 GH (Canada)
|
73.81 Scale score
Standard Deviation 18.686
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 VT (Canada)
|
66.63 Scale score
Standard Deviation 19.059
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 SF (Canada)
|
85.69 Scale score
Standard Deviation 20.937
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 RE (Canada)
|
84.74 Scale score
Standard Deviation 22.316
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 MH (Canada)
|
80.52 Scale score
Standard Deviation 16.659
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 PF (Czechia)
|
83.63 Scale score
Standard Deviation 16.758
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 RP (Czechia)
|
83.52 Scale score
Standard Deviation 20.371
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 BP (Czechia)
|
80.72 Scale score
Standard Deviation 23.278
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 GH (Czechia)
|
68.85 Scale score
Standard Deviation 18.579
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 VT (Czechia)
|
70.20 Scale score
Standard Deviation 17.658
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 SF (Czechia)
|
89.77 Scale score
Standard Deviation 17.686
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 RE (Czechia)
|
87.35 Scale score
Standard Deviation 18.853
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 MH (Czechia)
|
78.85 Scale score
Standard Deviation 15.813
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 PF (Czechia)
|
81.04 Scale score
Standard Deviation 20.182
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 RP (Czechia)
|
71.82 Scale score
Standard Deviation 23.074
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 BP (Czechia)
|
76.22 Scale score
Standard Deviation 25.263
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 GH (Czechia)
|
67.28 Scale score
Standard Deviation 19.827
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 VT (Czechia)
|
65.33 Scale score
Standard Deviation 18.155
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 SF (Czechia)
|
84.17 Scale score
Standard Deviation 21.684
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 RE (Czechia)
|
78.21 Scale score
Standard Deviation 21.121
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 MH (Czechia)
|
74.13 Scale score
Standard Deviation 17.039
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 PF (Czechia)
|
78.01 Scale score
Standard Deviation 22.368
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 RP (Czechia)
|
68.18 Scale score
Standard Deviation 22.493
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 BP (Czechia)
|
72.86 Scale score
Standard Deviation 25.494
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 GH (Czechia)
|
64.08 Scale score
Standard Deviation 20.318
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 VT (Czechia)
|
62.35 Scale score
Standard Deviation 18.222
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 SF (Czechia)
|
81.68 Scale score
Standard Deviation 22.531
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 RE (Czechia)
|
75.93 Scale score
Standard Deviation 22.099
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 MH (Czechia)
|
72.47 Scale score
Standard Deviation 16.970
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 PF (Czechia)
|
77.48 Scale score
Standard Deviation 22.752
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 RP (Czechia)
|
67.50 Scale score
Standard Deviation 22.564
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 BP (Czechia)
|
72.07 Scale score
Standard Deviation 25.893
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 GH (Czechia)
|
64.39 Scale score
Standard Deviation 20.053
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 VT (Czechia)
|
63.60 Scale score
Standard Deviation 17.688
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 SF (Czechia)
|
82.13 Scale score
Standard Deviation 22.341
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 RE (Czechia)
|
74.77 Scale score
Standard Deviation 22.306
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 PF (Estonia)
|
83.27 Scale score
Standard Deviation 18.040
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 RP (Estonia)
|
77.52 Scale score
Standard Deviation 26.681
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 BP (Estonia)
|
74.30 Scale score
Standard Deviation 24.729
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 GH (Estonia)
|
58.49 Scale score
Standard Deviation 19.050
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 VT (Estonia)
|
74.72 Scale score
Standard Deviation 17.041
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 RE (Estonia)
|
86.16 Scale score
Standard Deviation 21.264
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 RE (Estonia)
|
74.48 Scale score
Standard Deviation 26.156
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 MH (Estonia)
|
74.94 Scale score
Standard Deviation 17.531
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 PF (Estonia)
|
60.37 Scale score
Standard Deviation 26.153
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 RP (Estonia)
|
62.11 Scale score
Standard Deviation 27.161
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 VT (Finland)
|
70.90 Scale score
Standard Deviation 18.617
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 MH (Finland)
|
85.49 Scale score
Standard Deviation 13.528
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 RP (Finland)
|
81.29 Scale score
Standard Deviation 24.688
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 BP (Finland)
|
73.70 Scale score
Standard Deviation 22.313
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 GH (Finland)
|
68.25 Scale score
Standard Deviation 18.451
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 VT (Finland)
|
70.28 Scale score
Standard Deviation 18.764
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 SF (Finland)
|
91.13 Scale score
Standard Deviation 16.940
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 RE (Finland)
|
86.78 Scale score
Standard Deviation 20.806
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 MH (Finland)
|
84.90 Scale score
Standard Deviation 14.261
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 BP (Finland)
|
72.46 Scale score
Standard Deviation 22.635
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 GH (Finland)
|
66.89 Scale score
Standard Deviation 18.987
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 RE (Finland)
|
85.90 Scale score
Standard Deviation 21.204
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 MH (Finland)
|
84.54 Scale score
Standard Deviation 14.481
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 PF (France)
|
75.41 Scale score
Standard Deviation 24.712
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 RP (France)
|
73.50 Scale score
Standard Deviation 24.831
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 BP (France)
|
67.29 Scale score
Standard Deviation 23.946
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 GH (France)
|
64.74 Scale score
Standard Deviation 16.392
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 VT (France)
|
60.73 Scale score
Standard Deviation 18.170
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 SF (France)
|
80.61 Scale score
Standard Deviation 20.116
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 RE (France)
|
76.24 Scale score
Standard Deviation 24.041
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 MH (France)
|
67.97 Scale score
Standard Deviation 18.216
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 PF (France)
|
75.18 Scale score
Standard Deviation 24.455
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 RP (France)
|
70.95 Scale score
Standard Deviation 24.437
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 BP (France)
|
64.73 Scale score
Standard Deviation 23.409
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 GH (France)
|
62.80 Scale score
Standard Deviation 16.748
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 VT (France)
|
58.70 Scale score
Standard Deviation 18.280
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 SF (France)
|
76.55 Scale score
Standard Deviation 20.693
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 RE (France)
|
73.38 Scale score
Standard Deviation 23.899
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 MH (France)
|
66.77 Scale score
Standard Deviation 18.228
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 PF (France)
|
74.36 Scale score
Standard Deviation 24.684
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 RP (France)
|
68.23 Scale score
Standard Deviation 25.003
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 BP (France)
|
62.76 Scale score
Standard Deviation 23.949
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 GH (France)
|
61.46 Scale score
Standard Deviation 17.457
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 VT (France)
|
57.15 Scale score
Standard Deviation 19.107
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 SF (France)
|
74.86 Scale score
Standard Deviation 21.775
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 RE (France)
|
71.27 Scale score
Standard Deviation 24.405
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 MH (France)
|
65.37 Scale score
Standard Deviation 18.671
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 PF (France)
|
74.03 Scale score
Standard Deviation 24.824
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 RP (France)
|
67.99 Scale score
Standard Deviation 25.099
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 BP (France)
|
62.02 Scale score
Standard Deviation 22.966
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 GH (France)
|
60.60 Scale score
Standard Deviation 17.031
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 VT (France)
|
56.85 Scale score
Standard Deviation 18.659
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 SF (France)
|
73.68 Scale score
Standard Deviation 21.831
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 RE (France)
|
71.29 Scale score
Standard Deviation 24.172
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 MH (France)
|
65.49 Scale score
Standard Deviation 18.203
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 PF (Germany)
|
74.28 Scale score
Standard Deviation 24.865
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 RP (Germany)
|
72.36 Scale score
Standard Deviation 26.307
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 GH (Germany)
|
67.79 Scale score
Standard Deviation 17.909
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 VT (Germany)
|
66.06 Scale score
Standard Deviation 18.835
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 SF (Germany)
|
87.35 Scale score
Standard Deviation 19.367
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 RE (Germany)
|
80.80 Scale score
Standard Deviation 24.970
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 MH (Germany)
|
76.40 Scale score
Standard Deviation 17.804
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 PF (Germany)
|
70.55 Scale score
Standard Deviation 26.402
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 RP (Germany)
|
70.53 Scale score
Standard Deviation 27.114
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 BP (Germany)
|
68.40 Scale score
Standard Deviation 28.031
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 GH (Germany)
|
65.86 Scale score
Standard Deviation 18.435
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 VT (Germany)
|
64.07 Scale score
Standard Deviation 19.605
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 SF (Germany)
|
86.44 Scale score
Standard Deviation 21.019
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 RE (Germany)
|
78.88 Scale score
Standard Deviation 26.001
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 MH (Germany)
|
75.30 Scale score
Standard Deviation 18.230
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 PF (Germany)
|
69.01 Scale score
Standard Deviation 26.633
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 RP (Germany)
|
67.97 Scale score
Standard Deviation 27.948
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 BP (Germany)
|
66.77 Scale score
Standard Deviation 28.555
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 GH (Germany)
|
64.65 Scale score
Standard Deviation 18.682
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 VT (Germany)
|
62.50 Scale score
Standard Deviation 19.903
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 SF (Germany)
|
84.84 Scale score
Standard Deviation 21.200
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 RE (Germany)
|
77.77 Scale score
Standard Deviation 26.354
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 MH (Germany)
|
74.49 Scale score
Standard Deviation 18.575
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 PF (Germany)
|
66.53 Scale score
Standard Deviation 27.718
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 RP (Germany)
|
65.12 Scale score
Standard Deviation 28.052
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 BP (Germany)
|
64.79 Scale score
Standard Deviation 28.435
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 GH (Germany)
|
62.92 Scale score
Standard Deviation 19.191
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 VT (Germany)
|
60.45 Scale score
Standard Deviation 20.033
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 SF (Germany)
|
82.56 Scale score
Standard Deviation 23.166
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 RE (Germany)
|
75.57 Scale score
Standard Deviation 26.996
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 MH (Germany)
|
72.80 Scale score
Standard Deviation 18.705
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 PF (Hong Kong)
|
83.21 Scale score
Standard Deviation 18.057
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 RP (Hong Kong)
|
80.34 Scale score
Standard Deviation 21.511
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 BP (Hong Kong)
|
70.96 Scale score
Standard Deviation 23.972
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 GH (Hong Kong)
|
64.98 Scale score
Standard Deviation 18.295
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 VT (Hong Kong)
|
67.55 Scale score
Standard Deviation 18.230
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 SF (Hong Kong)
|
85.80 Scale score
Standard Deviation 18.176
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 RE (Hong Kong)
|
82.16 Scale score
Standard Deviation 19.210
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 MH (Hong Kong)
|
75.43 Scale score
Standard Deviation 16.891
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 PF (Hong Kong)
|
79.35 Scale score
Standard Deviation 20.242
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 RP (Hong Kong)
|
75.11 Scale score
Standard Deviation 23.850
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 BP (Hong Kong)
|
67.98 Scale score
Standard Deviation 24.349
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 GH (Hong Kong)
|
62.23 Scale score
Standard Deviation 19.396
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 VT (Hong Kong)
|
64.27 Scale score
Standard Deviation 19.121
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 SF (Hong Kong)
|
81.83 Scale score
Standard Deviation 21.223
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 RE (Hong Kong)
|
77.99 Scale score
Standard Deviation 22.505
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 MH (Hong Kong)
|
73.79 Scale score
Standard Deviation 17.471
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 PF (Hong Kong)
|
78.42 Scale score
Standard Deviation 21.721
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 RP (Hong Kong)
|
75.63 Scale score
Standard Deviation 24.198
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 BP (Hong Kong)
|
68.43 Scale score
Standard Deviation 23.730
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 GH (Hong Kong)
|
61.23 Scale score
Standard Deviation 20.163
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 VT (Hong Kong)
|
63.51 Scale score
Standard Deviation 19.771
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 SF (Hong Kong)
|
80.96 Scale score
Standard Deviation 21.922
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 RE (Hong Kong)
|
77.75 Scale score
Standard Deviation 23.055
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 MH (Hong Kong)
|
73.15 Scale score
Standard Deviation 16.489
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 PF (Hong Kong)
|
77.54 Scale score
Standard Deviation 22.833
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 RP (Hong Kong)
|
73.67 Scale score
Standard Deviation 24.805
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 BP (Hong Kong)
|
67.34 Scale score
Standard Deviation 24.483
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 GH (Hong Kong)
|
61.39 Scale score
Standard Deviation 19.740
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 VT (Hong Kong)
|
64.05 Scale score
Standard Deviation 20.721
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 SF (Hong Kong)
|
81.62 Scale score
Standard Deviation 21.797
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 RE (Hong Kong)
|
76.32 Scale score
Standard Deviation 24.373
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 MH (Hong Kong)
|
72.82 Scale score
Standard Deviation 17.329
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 PF (Italy)
|
86.53 Scale score
Standard Deviation 19.730
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 RP (Italy)
|
82.24 Scale score
Standard Deviation 23.022
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 BP (Italy)
|
77.60 Scale score
Standard Deviation 22.612
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 GH (Italy)
|
68.83 Scale score
Standard Deviation 16.936
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 VT (Italy)
|
69.02 Scale score
Standard Deviation 16.438
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 SF (Italy)
|
83.32 Scale score
Standard Deviation 18.086
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 RE (Italy)
|
81.83 Scale score
Standard Deviation 23.533
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 MH (Italy)
|
74.33 Scale score
Standard Deviation 16.931
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 PF (Italy)
|
87.31 Scale score
Standard Deviation 15.749
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 RP (Italy)
|
80.85 Scale score
Standard Deviation 22.119
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 BP (Italy)
|
76.25 Scale score
Standard Deviation 23.474
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 GH (Italy)
|
67.43 Scale score
Standard Deviation 15.923
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 VT (Italy)
|
67.05 Scale score
Standard Deviation 16.316
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 SF (Italy)
|
82.81 Scale score
Standard Deviation 18.593
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 RE (Italy)
|
83.11 Scale score
Standard Deviation 19.246
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 MH (Italy)
|
73.56 Scale score
Standard Deviation 15.655
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 PF (Italy)
|
86.19 Scale score
Standard Deviation 18.527
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 RP (Italy)
|
79.01 Scale score
Standard Deviation 23.544
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 BP (Italy)
|
74.54 Scale score
Standard Deviation 24.129
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 GH (Italy)
|
65.89 Scale score
Standard Deviation 16.558
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 VT (Italy)
|
66.65 Scale score
Standard Deviation 16.440
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 SF (Italy)
|
80.43 Scale score
Standard Deviation 19.963
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 RE (Italy)
|
82.50 Scale score
Standard Deviation 21.230
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 MH (Italy)
|
72.73 Scale score
Standard Deviation 16.689
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 PF (Italy)
|
84.73 Scale score
Standard Deviation 18.063
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 RP (Italy)
|
77.37 Scale score
Standard Deviation 23.479
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 BP (Italy)
|
73.01 Scale score
Standard Deviation 23.983
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 GH (Italy)
|
63.52 Scale score
Standard Deviation 17.528
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 VT (Italy)
|
63.63 Scale score
Standard Deviation 18.488
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 SF (Italy)
|
78.82 Scale score
Standard Deviation 20.455
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 RE (Italy)
|
79.55 Scale score
Standard Deviation 22.863
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 MH (Italy)
|
70.74 Scale score
Standard Deviation 17.479
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 PF (Japan)
|
88.88 Scale score
Standard Deviation 12.908
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 RP (Japan)
|
91.82 Scale score
Standard Deviation 16.302
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 BP (Japan)
|
82.43 Scale score
Standard Deviation 19.448
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 GH (Japan)
|
70.69 Scale score
Standard Deviation 15.760
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 VT (Japan)
|
73.62 Scale score
Standard Deviation 17.006
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 SF (Japan)
|
92.56 Scale score
Standard Deviation 14.706
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 RE (Japan)
|
92.63 Scale score
Standard Deviation 15.595
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 MH (Japan)
|
81.22 Scale score
Standard Deviation 15.266
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 PF (Japan)
|
89.69 Scale score
Standard Deviation 12.128
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 RP (Japan)
|
91.48 Scale score
Standard Deviation 17.297
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 BP (Japan)
|
80.18 Scale score
Standard Deviation 21.763
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 GH (Japan)
|
71.51 Scale score
Standard Deviation 16.647
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 VT (Japan)
|
73.72 Scale score
Standard Deviation 18.533
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 SF (Japan)
|
92.65 Scale score
Standard Deviation 15.728
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 RE (Japan)
|
92.71 Scale score
Standard Deviation 15.618
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 MH (Japan)
|
81.94 Scale score
Standard Deviation 16.363
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 PF (Japan)
|
87.94 Scale score
Standard Deviation 14.652
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 RP (Japan)
|
90.40 Scale score
Standard Deviation 18.839
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 BP (Japan)
|
80.13 Scale score
Standard Deviation 20.899
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 GH (Japan)
|
70.08 Scale score
Standard Deviation 17.053
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 VT (Japan)
|
72.86 Scale score
Standard Deviation 18.257
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 SF (Japan)
|
91.75 Scale score
Standard Deviation 16.104
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 RE (Japan)
|
92.62 Scale score
Standard Deviation 15.921
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 MH (Japan)
|
82.25 Scale score
Standard Deviation 15.763
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 PF (Japan)
|
87.65 Scale score
Standard Deviation 16.327
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 RP (Japan)
|
89.75 Scale score
Standard Deviation 19.328
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 BP (Japan)
|
80.38 Scale score
Standard Deviation 21.386
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 GH (Japan)
|
69.72 Scale score
Standard Deviation 17.798
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 VT (Japan)
|
71.77 Scale score
Standard Deviation 19.749
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 SF (Japan)
|
91.81 Scale score
Standard Deviation 16.776
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 RE (Japan)
|
91.44 Scale score
Standard Deviation 17.817
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 MH (Japan)
|
81.69 Scale score
Standard Deviation 16.549
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 PF (Republic of Korea)
|
67.77 Scale score
Standard Deviation 26.978
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 RP (Republic of Korea)
|
77.43 Scale score
Standard Deviation 28.253
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 BP (Republic of Korea)
|
77.21 Scale score
Standard Deviation 22.831
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 GH (Republic of Korea)
|
63.51 Scale score
Standard Deviation 17.871
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 VT (Republic of Korea)
|
62.41 Scale score
Standard Deviation 21.822
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 SF (Republic of Korea)
|
88.91 Scale score
Standard Deviation 18.000
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 RE (Republic of Korea)
|
82.90 Scale score
Standard Deviation 25.455
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 MH (Republic of Korea)
|
77.15 Scale score
Standard Deviation 17.804
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 PF (Republic of Korea)
|
68.09 Scale score
Standard Deviation 25.214
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 RP (Republic of Korea)
|
79.45 Scale score
Standard Deviation 27.205
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 BP (Republic of Korea)
|
76.12 Scale score
Standard Deviation 23.543
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 GH (Republic of Korea)
|
60.18 Scale score
Standard Deviation 17.724
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 VT (Republic of Korea)
|
58.10 Scale score
Standard Deviation 22.111
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 SF (Republic of Korea)
|
88.24 Scale score
Standard Deviation 19.223
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 RE (Republic of Korea)
|
82.54 Scale score
Standard Deviation 25.203
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 MH (Republic of Korea)
|
73.41 Scale score
Standard Deviation 19.630
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 PF (Republic of Korea)
|
68.22 Scale score
Standard Deviation 27.279
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 RP (Republic of Korea)
|
77.15 Scale score
Standard Deviation 29.110
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 BP (Republic of Korea)
|
76.05 Scale score
Standard Deviation 22.808
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 GH (Republic of Korea)
|
59.59 Scale score
Standard Deviation 17.585
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 VT (Republic of Korea)
|
56.19 Scale score
Standard Deviation 20.988
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 SF (Republic of Korea)
|
88.00 Scale score
Standard Deviation 18.962
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 RE (Republic of Korea)
|
83.44 Scale score
Standard Deviation 24.461
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 MH (Republic of Korea)
|
73.31 Scale score
Standard Deviation 18.120
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 PF (Republic of Korea)
|
68.77 Scale score
Standard Deviation 24.394
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 RP (Republic of Korea)
|
77.22 Scale score
Standard Deviation 28.780
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 BP (Republic of Korea)
|
75.94 Scale score
Standard Deviation 23.169
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 GH (Republic of Korea)
|
60.91 Scale score
Standard Deviation 18.678
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 VT (Republic of Korea)
|
59.99 Scale score
Standard Deviation 21.325
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 SF (Republic of Korea)
|
87.37 Scale score
Standard Deviation 20.181
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 RE (Republic of Korea)
|
82.99 Scale score
Standard Deviation 24.826
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 MH (Republic of Korea)
|
72.97 Scale score
Standard Deviation 18.246
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 PF (Mexico)
|
76.06 Scale score
Standard Deviation 24.708
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 RP (Mexico)
|
75.05 Scale score
Standard Deviation 25.724
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 BP (Mexico)
|
73.03 Scale score
Standard Deviation 24.251
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 GH (Mexico)
|
64.84 Scale score
Standard Deviation 21.693
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 VT (Mexico)
|
68.62 Scale score
Standard Deviation 19.869
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 SF (Mexico)
|
81.98 Scale score
Standard Deviation 20.943
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 RE (Mexico)
|
77.19 Scale score
Standard Deviation 23.958
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 MH (Mexico)
|
72.17 Scale score
Standard Deviation 19.691
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 PF (Mexico)
|
73.73 Scale score
Standard Deviation 25.765
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 RP (Mexico)
|
76.33 Scale score
Standard Deviation 28.535
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 BP (Mexico)
|
71.34 Scale score
Standard Deviation 27.257
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 GH (Mexico)
|
63.83 Scale score
Standard Deviation 24.663
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 VT (Mexico)
|
67.13 Scale score
Standard Deviation 23.573
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 SF (Mexico)
|
84.19 Scale score
Standard Deviation 23.017
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 RE (Mexico)
|
81.86 Scale score
Standard Deviation 25.777
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 MH (Mexico)
|
73.26 Scale score
Standard Deviation 22.822
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 PF (Mexico)
|
69.20 Scale score
Standard Deviation 27.709
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 RP (Mexico)
|
76.59 Scale score
Standard Deviation 27.985
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 BP (Mexico)
|
70.63 Scale score
Standard Deviation 26.378
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 GH (Mexico)
|
61.32 Scale score
Standard Deviation 24.274
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 VT (Mexico)
|
65.73 Scale score
Standard Deviation 24.304
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 SF (Mexico)
|
83.33 Scale score
Standard Deviation 22.879
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 RE (Mexico)
|
80.72 Scale score
Standard Deviation 25.848
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 MH (Mexico)
|
73.30 Scale score
Standard Deviation 22.825
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 PF (Mexico)
|
65.25 Scale score
Standard Deviation 28.863
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 RP (Mexico)
|
70.65 Scale score
Standard Deviation 29.950
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 BP (Mexico)
|
67.32 Scale score
Standard Deviation 26.220
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 GH (Mexico)
|
59.99 Scale score
Standard Deviation 23.909
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 VT (Mexico)
|
63.93 Scale score
Standard Deviation 23.206
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 SF (Mexico)
|
78.10 Scale score
Standard Deviation 25.405
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 RE (Mexico)
|
73.58 Scale score
Standard Deviation 28.335
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 MH (Mexico)
|
71.19 Scale score
Standard Deviation 21.882
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 PF (Spain)
|
79.28 Scale score
Standard Deviation 21.596
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 RP (Spain)
|
87.75 Scale score
Standard Deviation 21.338
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 BP (Spain)
|
76.05 Scale score
Standard Deviation 24.753
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 GH (Spain)
|
68.73 Scale score
Standard Deviation 18.313
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 VT (Spain)
|
74.00 Scale score
Standard Deviation 20.813
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 SF (Spain)
|
91.18 Scale score
Standard Deviation 17.192
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 RE (Spain)
|
91.34 Scale score
Standard Deviation 17.970
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 MH (Spain)
|
80.26 Scale score
Standard Deviation 19.405
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 PF (Spain)
|
75.49 Scale score
Standard Deviation 24.090
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 RP (Spain)
|
85.12 Scale score
Standard Deviation 23.307
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 BP (Spain)
|
71.39 Scale score
Standard Deviation 26.702
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 GH (Spain)
|
67.05 Scale score
Standard Deviation 19.516
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 VT (Spain)
|
68.42 Scale score
Standard Deviation 23.055
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 SF (Spain)
|
88.13 Scale score
Standard Deviation 21.275
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 RE (Spain)
|
89.69 Scale score
Standard Deviation 20.295
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 MH (Spain)
|
76.22 Scale score
Standard Deviation 20.698
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 PF (Spain)
|
74.18 Scale score
Standard Deviation 24.468
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 RP (Spain)
|
81.33 Scale score
Standard Deviation 26.181
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 BP (Spain)
|
69.64 Scale score
Standard Deviation 27.123
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 GH (Spain)
|
66.01 Scale score
Standard Deviation 19.368
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 VT (Spain)
|
66.97 Scale score
Standard Deviation 23.292
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 SF (Spain)
|
87.43 Scale score
Standard Deviation 21.646
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 RE (Spain)
|
88.43 Scale score
Standard Deviation 21.561
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 MH (Spain)
|
75.64 Scale score
Standard Deviation 20.759
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 PF (Spain)
|
72.59 Scale score
Standard Deviation 25.686
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 RP (Spain)
|
81.18 Scale score
Standard Deviation 26.008
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 BP (Spain)
|
69.62 Scale score
Standard Deviation 26.974
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 GH (Spain)
|
64.83 Scale score
Standard Deviation 19.604
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 VT (Spain)
|
65.44 Scale score
Standard Deviation 23.097
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 SF (Spain)
|
87.16 Scale score
Standard Deviation 21.780
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 RE (Spain)
|
88.97 Scale score
Standard Deviation 20.277
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 MH (Spain)
|
75.14 Scale score
Standard Deviation 20.731
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 PF (Sweden)
|
84.11 Scale score
Standard Deviation 18.733
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 RP (Sweden)
|
88.84 Scale score
Standard Deviation 19.401
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 BP (Sweden)
|
79.07 Scale score
Standard Deviation 22.648
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 GH (Sweden)
|
80.36 Scale score
Standard Deviation 17.091
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 VT (Sweden)
|
76.15 Scale score
Standard Deviation 18.033
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 SF (Sweden)
|
93.78 Scale score
Standard Deviation 14.547
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 RE (Sweden)
|
92.59 Scale score
Standard Deviation 16.008
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 MH (Sweden)
|
87.01 Scale score
Standard Deviation 13.481
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 PF (Sweden)
|
81.48 Scale score
Standard Deviation 20.319
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 RP (Sweden)
|
85.40 Scale score
Standard Deviation 22.576
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 BP (Sweden)
|
75.90 Scale score
Standard Deviation 24.641
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 GH (Sweden)
|
76.00 Scale score
Standard Deviation 18.800
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 VT (Sweden)
|
73.01 Scale score
Standard Deviation 20.496
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 SF (Sweden)
|
91.60 Scale score
Standard Deviation 17.418
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 RE (Sweden)
|
90.96 Scale score
Standard Deviation 18.262
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 MH (Sweden)
|
86.18 Scale score
Standard Deviation 14.848
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 PF (Sweden)
|
80.67 Scale score
Standard Deviation 20.988
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 RP (Sweden)
|
84.62 Scale score
Standard Deviation 23.270
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 BP (Sweden)
|
75.01 Scale score
Standard Deviation 24.387
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 GH (Sweden)
|
75.90 Scale score
Standard Deviation 19.298
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 VT (Sweden)
|
71.78 Scale score
Standard Deviation 20.945
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 SF (Sweden)
|
90.58 Scale score
Standard Deviation 18.238
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 RE (Sweden)
|
90.08 Scale score
Standard Deviation 18.878
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 MH (Sweden)
|
85.22 Scale score
Standard Deviation 15.521
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 PF (Sweden)
|
79.20 Scale score
Standard Deviation 21.873
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 RP (Sweden)
|
82.09 Scale score
Standard Deviation 25.357
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 BP (Sweden)
|
74.38 Scale score
Standard Deviation 24.731
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 GH (Sweden)
|
74.19 Scale score
Standard Deviation 19.653
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 VT (Sweden)
|
70.77 Scale score
Standard Deviation 21.471
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 SF (Sweden)
|
90.26 Scale score
Standard Deviation 18.614
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 RE (Sweden)
|
88.83 Scale score
Standard Deviation 20.313
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 MH (Sweden)
|
84.81 Scale score
Standard Deviation 15.910
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 PF (Taiwan)
|
83.07 Scale score
Standard Deviation 20.550
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 RP (Taiwan)
|
83.88 Scale score
Standard Deviation 21.920
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 BP (Taiwan)
|
83.37 Scale score
Standard Deviation 19.421
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 GH (Taiwan)
|
70.15 Scale score
Standard Deviation 18.885
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 VT (Taiwan)
|
72.29 Scale score
Standard Deviation 18.430
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 SF (Taiwan)
|
90.41 Scale score
Standard Deviation 14.557
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 RE (Taiwan)
|
86.56 Scale score
Standard Deviation 19.473
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 MH (Taiwan)
|
78.06 Scale score
Standard Deviation 16.593
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 PF (Taiwan)
|
83.38 Scale score
Standard Deviation 18.693
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 RP (Taiwan)
|
82.95 Scale score
Standard Deviation 22.339
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 BP (Taiwan)
|
81.58 Scale score
Standard Deviation 20.215
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 GH (Taiwan)
|
69.11 Scale score
Standard Deviation 19.118
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 VT (Taiwan)
|
70.03 Scale score
Standard Deviation 19.270
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 SF (Taiwan)
|
89.74 Scale score
Standard Deviation 15.538
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 RE (Taiwan)
|
84.98 Scale score
Standard Deviation 19.686
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 MH (Taiwan)
|
77.42 Scale score
Standard Deviation 16.610
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 PF (Taiwan)
|
82.08 Scale score
Standard Deviation 19.937
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 RP (Taiwan)
|
82.18 Scale score
Standard Deviation 23.207
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 BP (Taiwan)
|
80.84 Scale score
Standard Deviation 20.720
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 GH (Taiwan)
|
68.56 Scale score
Standard Deviation 20.296
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 VT (Taiwan)
|
70.04 Scale score
Standard Deviation 19.068
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 SF (Taiwan)
|
89.70 Scale score
Standard Deviation 15.829
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 RE (Taiwan)
|
84.86 Scale score
Standard Deviation 20.402
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 MH (Taiwan)
|
77.00 Scale score
Standard Deviation 17.208
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 PF (Taiwan)
|
80.62 Scale score
Standard Deviation 21.330
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 RP (Taiwan)
|
78.40 Scale score
Standard Deviation 25.194
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 BP (Taiwan)
|
79.55 Scale score
Standard Deviation 21.425
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 GH (Taiwan)
|
67.12 Scale score
Standard Deviation 20.107
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 VT (Taiwan)
|
68.57 Scale score
Standard Deviation 19.453
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 SF (Taiwan)
|
87.10 Scale score
Standard Deviation 17.663
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 RE (Taiwan)
|
81.25 Scale score
Standard Deviation 22.276
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 MH (Taiwan)
|
76.20 Scale score
Standard Deviation 17.290
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 PF (United Kingdom)
|
71.71 Scale score
Standard Deviation 27.696
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 RP (United Kingdom)
|
79.47 Scale score
Standard Deviation 26.123
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 BP (United Kingdom)
|
73.04 Scale score
Standard Deviation 26.098
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 GH (United Kingdom)
|
71.43 Scale score
Standard Deviation 19.664
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 VT (United Kingdom)
|
64.93 Scale score
Standard Deviation 20.355
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 SF (United Kingdom)
|
88.02 Scale score
Standard Deviation 21.772
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 RE (United Kingdom)
|
87.82 Scale score
Standard Deviation 22.674
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 MH (United Kingdom)
|
80.46 Scale score
Standard Deviation 17.348
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 PF (United Kingdom)
|
68.78 Scale score
Standard Deviation 29.011
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 RP (United Kingdom)
|
73.59 Scale score
Standard Deviation 30.401
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 BP (United Kingdom)
|
68.88 Scale score
Standard Deviation 27.303
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 GH (United Kingdom)
|
67.55 Scale score
Standard Deviation 21.359
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 VT (United Kingdom)
|
60.94 Scale score
Standard Deviation 21.934
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 SF (United Kingdom)
|
85.18 Scale score
Standard Deviation 24.093
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 RE (United Kingdom)
|
85.24 Scale score
Standard Deviation 25.645
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 MH (United Kingdom)
|
79.24 Scale score
Standard Deviation 18.331
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 PF (United Kingdom)
|
67.69 Scale score
Standard Deviation 28.942
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 RP (United Kingdom)
|
72.59 Scale score
Standard Deviation 29.682
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 BP (United Kingdom)
|
67.81 Scale score
Standard Deviation 27.447
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 GH (United Kingdom)
|
67.53 Scale score
Standard Deviation 21.378
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 VT (United Kingdom)
|
59.99 Scale score
Standard Deviation 22.567
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 SF (United Kingdom)
|
82.92 Scale score
Standard Deviation 26.021
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 RE (United Kingdom)
|
83.17 Scale score
Standard Deviation 26.731
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 MH (United Kingdom)
|
78.18 Scale score
Standard Deviation 19.361
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 PF (United Kingdom)
|
66.64 Scale score
Standard Deviation 28.795
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 RP (United Kingdom)
|
71.46 Scale score
Standard Deviation 29.715
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 BP (United Kingdom)
|
67.74 Scale score
Standard Deviation 27.445
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 GH (United Kingdom)
|
67.39 Scale score
Standard Deviation 20.666
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 VT (United Kingdom)
|
59.64 Scale score
Standard Deviation 21.532
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 SF (United Kingdom)
|
82.92 Scale score
Standard Deviation 24.958
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 RE (United Kingdom)
|
83.37 Scale score
Standard Deviation 25.844
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 MH (United Kingdom)
|
78.61 Scale score
Standard Deviation 18.453
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 PF (United States)
|
76.45 Scale score
Standard Deviation 23.632
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 RP (United States)
|
81.58 Scale score
Standard Deviation 23.473
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 BP (United States)
|
75.20 Scale score
Standard Deviation 21.417
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 GH (United States)
|
78.06 Scale score
Standard Deviation 16.471
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 VT (United States)
|
69.99 Scale score
Standard Deviation 17.564
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 SF (United States)
|
92.28 Scale score
Standard Deviation 16.120
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 RE (United States)
|
90.44 Scale score
Standard Deviation 18.574
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 0 - SF36 MH (United States)
|
84.73 Scale score
Standard Deviation 13.554
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 PF (United States)
|
74.70 Scale score
Standard Deviation 25.252
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 RP (United States)
|
78.58 Scale score
Standard Deviation 26.202
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 BP (United States)
|
73.02 Scale score
Standard Deviation 23.499
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 GH (United States)
|
75.44 Scale score
Standard Deviation 17.797
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 VT (United States)
|
67.13 Scale score
Standard Deviation 18.980
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 SF (United States)
|
89.99 Scale score
Standard Deviation 18.818
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 RE (United States)
|
88.06 Scale score
Standard Deviation 21.433
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 14 - SF36 MH (United States)
|
83.61 Scale score
Standard Deviation 14.733
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 PF (United States)
|
73.93 Scale score
Standard Deviation 25.438
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 RP (United States)
|
78.00 Scale score
Standard Deviation 26.125
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 BP (United States)
|
73.01 Scale score
Standard Deviation 23.580
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 GH (United States)
|
74.92 Scale score
Standard Deviation 18.181
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 VT (United States)
|
66.95 Scale score
Standard Deviation 19.411
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 SF (United States)
|
89.94 Scale score
Standard Deviation 19.038
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 RE (United States)
|
87.83 Scale score
Standard Deviation 21.258
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 26 - SF36 MH (United States)
|
83.48 Scale score
Standard Deviation 15.118
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 PF (United States)
|
71.66 Scale score
Standard Deviation 26.334
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 RP (United States)
|
75.97 Scale score
Standard Deviation 26.785
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 BP (United States)
|
71.31 Scale score
Standard Deviation 23.682
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 GH (United States)
|
73.23 Scale score
Standard Deviation 18.699
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 VT (United States)
|
65.74 Scale score
Standard Deviation 19.480
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 SF (United States)
|
88.78 Scale score
Standard Deviation 19.795
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 RE (United States)
|
87.28 Scale score
Standard Deviation 22.058
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Month 38 - SF36 MH (United States)
|
83.20 Scale score
Standard Deviation 15.151
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: At Month 0, 14, 26 and 38Population: Analysis was performed on all subjects included in the Total Vaccinated Cohort (TVC) of Zoster-064
The EQ-5D questionnaire is a generic measure of health status that provides a simple descriptive profile and a single index value. The EQ-5D defines health in terms of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each item has 3 possible responses (No symptoms, Moderate symptoms, Extreme symptoms). The 5 items are then combined to generate health profiles that are subsequently converted to a continuous single index utility score using a one to one matching. Country or region-specific value sets are used for the score conversion. The scores range from less than 0 (where 0 is the value of a health state equivalent to dead) to 1 (the value of full health), with higher scores indicating higher health utility. The EQ-5D also contains a visual analogue scale (VAS). The VAS records the respondent's self-rated health on a vertical scale, ranging from 0(worst imaginable health state) to 100(best imaginable health state).
Outcome measures
| Measure |
Overall Group
n=3128 Participants
Adults aged ≥50 years of age in the Zoster-064 TVC who received herpes zoster subunit (HZ/su) vaccine or Placebo in Zoster-006/022 study
|
Non-Frail-Placebo
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as non-frail.
|
Pre-Frail-HZ/su
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were categorized as pre-frail.
|
Pre-Frail-Placebo
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as pre-frail.
|
Frail-HZ/su
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were categorized as frail.
|
Frail-Placebo
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as frail.
|
Unknown-HZ/su
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were not assigned a frailty category.
|
Unknown-Placebo
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were not assigned a frailty category.
|
|---|---|---|---|---|---|---|---|---|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 0 - EQ5D Utility (Brazil)
|
0.8565 Scale score
Standard Deviation 0.14387
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 0 - EQ5D VAS (Brazil)
|
82.92 Scale score
Standard Deviation 15.561
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 14 - EQ5D Utility (Brazil)
|
0.8524 Scale score
Standard Deviation 0.14637
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 14 - EQ5D VAS (Brazil)
|
81.57 Scale score
Standard Deviation 16.303
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 26 - EQ5D Utility (Brazil)
|
0.8535 Scale score
Standard Deviation 0.14893
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 26 - EQ5D VAS (Brazil)
|
81.96 Scale score
Standard Deviation 15.919
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 38 - EQ5D Utility (Brazil)
|
0.8410 Scale score
Standard Deviation 0.16028
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 38 - EQ5D VAS (Brazil)
|
81.41 Scale score
Standard Deviation 16.253
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 0 - EQ5D Utility (Canada)
|
0.8894 Scale score
Standard Deviation 0.12153
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 0 - EQ5D VAS (Canada)
|
83.75 Scale score
Standard Deviation 12.586
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 14 - EQ5D Utility (Canada)
|
0.8647 Scale score
Standard Deviation 0.14416
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 14 - EQ5D VAS (Canada)
|
81.59 Scale score
Standard Deviation 13.743
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 26 - EQ5D Utility (Canada)
|
0.8649 Scale score
Standard Deviation 0.13286
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 26 - EQ5D VAS (Canada)
|
81.03 Scale score
Standard Deviation 14.370
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 38 - EQ5D Utility (Canada)
|
0.8515 Scale score
Standard Deviation 0.13904
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 38 - EQ5D VAS (Canada)
|
80.23 Scale score
Standard Deviation 15.018
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 0 - EQ5D Utility (Czechia)
|
0.8724 Scale score
Standard Deviation 0.13090
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 0 - EQ5D VAS (Czechia)
|
83.60 Scale score
Standard Deviation 13.604
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 14 - EQ5D Utility (Czechia)
|
0.8214 Scale score
Standard Deviation 0.16054
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 14 - EQ5D VAS (Czechia)
|
83.61 Scale score
Standard Deviation 15.134
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 26 - EQ5D Utility (Czechia)
|
0.8034 Scale score
Standard Deviation 0.16000
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 26 - EQ5D VAS (Czechia)
|
81.24 Scale score
Standard Deviation 15.485
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 38 - EQ5D Utility (Czechia)
|
0.8080 Scale score
Standard Deviation 0.16581
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 38 - EQ5D VAS (Czechia)
|
81.88 Scale score
Standard Deviation 15.349
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 0 - EQ5D Utility (Estonia)
|
0.8393 Scale score
Standard Deviation 0.13827
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 0 - EQ5D VAS (Estonia)
|
71.57 Scale score
Standard Deviation 16.882
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 14 - EQ5D Utility (Estonia)
|
0.7796 Scale score
Standard Deviation 0.16461
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 14 - EQ5D VAS (Estonia)
|
71.61 Scale score
Standard Deviation 17.646
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 26 - EQ5D Utility (Estonia)
|
0.7176 Scale score
Standard Deviation 0.17669
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 26 - EQ5D VAS (Estonia)
|
66.39 Scale score
Standard Deviation 19.086
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 38 - EQ5D Utility (Estonia)
|
0.6800 Scale score
Standard Deviation 0.16682
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 38 - EQ5D VAS (Estonia)
|
64.89 Scale score
Standard Deviation 18.325
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 0 - EQ5D Utility (Finland)
|
0.8767 Scale score
Standard Deviation 0.15909
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 0 - EQ5D VAS (Finland)
|
83.57 Scale score
Standard Deviation 11.773
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 14 - EQ5D Utility (Finland)
|
0.8415 Scale score
Standard Deviation 0.17068
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 14 - EQ5D VAS (Finland)
|
81.15 Scale score
Standard Deviation 13.553
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 26 - EQ5D Utility (Finland)
|
0.8367 Scale score
Standard Deviation 0.17273
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 26 - EQ5D VAS (Finland)
|
80.89 Scale score
Standard Deviation 13.565
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 38 - EQ5D Utility (Finland)
|
0.8249 Scale score
Standard Deviation 0.17615
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 38 - EQ5D VAS (Finland)
|
80.22 Scale score
Standard Deviation 13.795
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 0 - EQ5D Utility (France)
|
0.8266 Scale score
Standard Deviation 0.20137
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 0 - EQ5D VAS (France)
|
74.39 Scale score
Standard Deviation 15.885
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 14 - EQ5D Utility (France)
|
0.8139 Scale score
Standard Deviation 0.22983
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 14 - EQ5D VAS (France)
|
73.30 Scale score
Standard Deviation 15.614
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 26 - EQ5D Utility (France)
|
0.8094 Scale score
Standard Deviation 0.23680
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 26 - EQ5D VAS (France)
|
72.97 Scale score
Standard Deviation 16.001
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 38 - EQ5D Utility (France)
|
0.7981 Scale score
Standard Deviation 0.24427
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 38 - EQ5D VAS (France)
|
73.44 Scale score
Standard Deviation 15.264
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 0 - EQ5D Utility (Germany)
|
0.8877 Scale score
Standard Deviation 0.16705
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 0 - EQ5D VAS (Germany)
|
77.11 Scale score
Standard Deviation 17.322
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 14 - EQ5D Utility (Germany)
|
0.8644 Scale score
Standard Deviation 0.18635
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 14 - EQ5D VAS (Germany)
|
74.09 Scale score
Standard Deviation 18.406
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 26 - EQ5D Utility (Germany)
|
0.8561 Scale score
Standard Deviation 0.19313
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 26 - EQ5D VAS (Germany)
|
72.47 Scale score
Standard Deviation 18.917
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 38 - EQ5D Utility (Germany)
|
0.8335 Scale score
Standard Deviation 0.20997
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 38 - EQ5D VAS (Germany)
|
70.79 Scale score
Standard Deviation 19.049
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 0 - EQ5D Utility (Hong Kong)
|
0.8743 Scale score
Standard Deviation 0.14053
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 0 - EQ5D VAS (Hong Kong)
|
82.32 Scale score
Standard Deviation 12.502
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 14 - EQ5D Utility (Hong Kong)
|
0.8398 Scale score
Standard Deviation 0.15518
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 14 - EQ5D VAS (Hong Kong)
|
81.14 Scale score
Standard Deviation 13.191
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 26 - EQ5D Utility (Hong Kong)
|
0.8463 Scale score
Standard Deviation 0.15796
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 26 - EQ5D VAS (Hong Kong)
|
79.65 Scale score
Standard Deviation 14.173
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 38 - EQ5D Utility (Hong Kong)
|
0.8393 Scale score
Standard Deviation 0.15566
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 38 - EQ5D VAS (Hong Kong)
|
80.61 Scale score
Standard Deviation 13.669
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 0 - EQ5D Utility (Italy)
|
0.8219 Scale score
Standard Deviation 0.14860
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 0 - EQ5D VAS (Italy)
|
79.80 Scale score
Standard Deviation 13.270
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 14 - EQ5D Utility (Italy)
|
0.8383 Scale score
Standard Deviation 0.13899
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 14 - EQ5D VAS (Italy)
|
79.72 Scale score
Standard Deviation 13.041
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 26 - EQ5D Utility (Italy)
|
0.8398 Scale score
Standard Deviation 0.14228
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 26 - EQ5D VAS (Italy)
|
78.84 Scale score
Standard Deviation 12.701
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 38 - EQ5D Utility (Italy)
|
0.8173 Scale score
Standard Deviation 0.16055
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 38 - EQ5D VAS (Italy)
|
77.19 Scale score
Standard Deviation 14.648
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 0 - EQ5D Utility (Japan)
|
0.9139 Scale score
Standard Deviation 0.13118
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 0 - EQ5D VAS (Japan)
|
80.43 Scale score
Standard Deviation 12.559
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 14 - EQ5D Utility (Japan)
|
0.9011 Scale score
Standard Deviation 0.13948
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 14 - EQ5D VAS (Japan)
|
81.53 Scale score
Standard Deviation 12.924
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 26 - EQ5D Utility (Japan)
|
0.8899 Scale score
Standard Deviation 0.13631
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 26 - EQ5D VAS (Japan)
|
81.76 Scale score
Standard Deviation 13.591
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 38 - EQ5D Utility (Japan)
|
0.8946 Scale score
Standard Deviation 0.14504
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 38 - EQ5D VAS (Japan)
|
80.65 Scale score
Standard Deviation 13.332
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 0 - EQ5D Utility (Republic of Korea)
|
0.8263 Scale score
Standard Deviation 0.16773
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 0 - EQ5D VAS (Republic of Korea)
|
79.81 Scale score
Standard Deviation 13.754
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 14 - EQ5D Utility (Republic of Korea)
|
0.8050 Scale score
Standard Deviation 0.17430
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 14 - EQ5D VAS (Republic of Korea)
|
76.95 Scale score
Standard Deviation 15.411
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 26 - EQ5D Utility (Republic of Korea)
|
0.8120 Scale score
Standard Deviation 0.16588
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 26 - EQ5D VAS (Republic of Korea)
|
76.53 Scale score
Standard Deviation 14.551
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 38 - EQ5D Utility (Republic of Korea)
|
0.8140 Scale score
Standard Deviation 0.18373
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 38 - EQ5D VAS (Republic of Korea)
|
75.97 Scale score
Standard Deviation 14.418
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 0 - EQ5D Utility (Mexico)
|
0.8863 Scale score
Standard Deviation 0.13315
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 0 - EQ5D VAS (Mexico)
|
83.57 Scale score
Standard Deviation 13.337
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 14 - EQ5D Utility (Mexico)
|
0.8733 Scale score
Standard Deviation 0.14923
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 14 - EQ5D VAS (Mexico)
|
83.11 Scale score
Standard Deviation 13.943
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 26 - EQ5D Utility (Mexico)
|
0.8615 Scale score
Standard Deviation 0.16050
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 26 - EQ5D VAS (Mexico)
|
81.96 Scale score
Standard Deviation 16.173
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 38 - EQ5D Utility (Mexico)
|
0.8465 Scale score
Standard Deviation 0.16123
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 38 - EQ5D VAS (Mexico)
|
80.49 Scale score
Standard Deviation 17.163
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 0 - EQ5D Utility (Spain)
|
0.8827 Scale score
Standard Deviation 0.19725
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 0 - EQ5D VAS (Spain)
|
79.44 Scale score
Standard Deviation 16.744
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 14 - EQ5D Utility (Spain)
|
0.8372 Scale score
Standard Deviation 0.23163
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 14 - EQ5D VAS (Spain)
|
75.42 Scale score
Standard Deviation 17.281
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 26 - EQ5D Utility (Spain)
|
0.8265 Scale score
Standard Deviation 0.24231
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 26 - EQ5D VAS (Spain)
|
75.71 Scale score
Standard Deviation 16.869
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 38 - EQ5D Utility (Spain)
|
0.8236 Scale score
Standard Deviation 0.24430
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 38 - EQ5D VAS (Spain)
|
74.97 Scale score
Standard Deviation 17.471
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 0 - EQ5D Utility (Sweden)
|
0.8527 Scale score
Standard Deviation 0.13410
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 0 - EQ5D VAS (Sweden)
|
85.05 Scale score
Standard Deviation 12.622
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 14 - EQ5D Utility (Sweden)
|
0.8387 Scale score
Standard Deviation 0.14270
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 14 - EQ5D VAS (Sweden)
|
82.31 Scale score
Standard Deviation 14.782
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 26 - EQ5D Utility (Sweden)
|
0.8371 Scale score
Standard Deviation 0.14325
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 26 - EQ5D VAS (Sweden)
|
82.19 Scale score
Standard Deviation 14.924
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 38 - EQ5D Utility (Sweden)
|
0.8191 Scale score
Standard Deviation 0.14856
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 38 - EQ5D VAS (Sweden)
|
81.11 Scale score
Standard Deviation 15.993
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 0 - EQ5D Utility (Taiwan)
|
0.9159 Scale score
Standard Deviation 0.12941
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 0 - EQ5D VAS (Taiwan)
|
83.20 Scale score
Standard Deviation 11.888
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 14 - EQ5D Utility (Taiwan)
|
0.9114 Scale score
Standard Deviation 0.13530
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 14 - EQ5D VAS (Taiwan)
|
82.25 Scale score
Standard Deviation 12.466
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 26 - EQ5D Utility (Taiwan)
|
0.9018 Scale score
Standard Deviation 0.14211
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 26 - EQ5D VAS (Taiwan)
|
82.88 Scale score
Standard Deviation 12.412
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 38 - EQ5D Utility (Taiwan)
|
0.8927 Scale score
Standard Deviation 0.15029
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 38 - EQ5D VAS (Taiwan)
|
81.61 Scale score
Standard Deviation 12.684
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 0 - EQ5D Utility (United Kingdom)
|
0.8069 Scale score
Standard Deviation 0.22841
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 0 - EQ5D VAS (United Kingdom)
|
79.37 Scale score
Standard Deviation 16.162
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 14 - EQ5D Utility (United Kingdom)
|
0.7743 Scale score
Standard Deviation 0.26018
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 14 - EQ5D VAS (United Kingdom)
|
77.47 Scale score
Standard Deviation 17.954
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 26 - EQ5D Utility (United Kingdom)
|
0.7535 Scale score
Standard Deviation 0.27379
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 26 - EQ5D VAS (United Kingdom)
|
76.58 Scale score
Standard Deviation 18.074
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 38 - EQ5D Utility (United Kingdom)
|
0.7569 Scale score
Standard Deviation 0.26046
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 38 - EQ5D VAS (United Kingdom)
|
76.98 Scale score
Standard Deviation 17.609
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 0 - EQ5D Utility (United States)
|
0.8843 Scale score
Standard Deviation 0.12499
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 0 - EQ5D VAS (United States)
|
85.22 Scale score
Standard Deviation 12.555
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 14 - EQ5D Utility (United States)
|
0.8747 Scale score
Standard Deviation 0.14000
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 14 - EQ5D VAS (United States)
|
84.06 Scale score
Standard Deviation 14.054
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 26 - EQ5D Utility (United States)
|
0.8722 Scale score
Standard Deviation 0.13899
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 26 - EQ5D VAS (United States)
|
83.63 Scale score
Standard Deviation 14.344
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 38 - EQ5D Utility (United States)
|
0.8576 Scale score
Standard Deviation 0.14879
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 38 - EQ5D VAS (United States)
|
82.75 Scale score
Standard Deviation 14.788
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 0 - EQ5D Utility (Australia)
|
0.8072 Scale score
Standard Deviation 0.19966
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 0 - EQ5D VAS (Australia)
|
85.43 Scale score
Standard Deviation 13.031
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 14 - EQ5D Utility (Australia)
|
0.7671 Scale score
Standard Deviation 0.19586
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 14 - EQ5D VAS (Australia)
|
81.48 Scale score
Standard Deviation 14.544
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 26 - EQ5D Utility (Australia)
|
0.7582 Scale score
Standard Deviation 0.20781
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 26 - EQ5D VAS (Australia)
|
81.24 Scale score
Standard Deviation 16.066
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 38 - EQ5D Utility (Australia)
|
0.7589 Scale score
Standard Deviation 0.19839
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Month 38 - EQ5D VAS (Australia)
|
80.86 Scale score
Standard Deviation 15.135
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: During the entire study period (3 to 5 year period following Day 0)Population: Analysis was performed on all subjects in the Modified Total Vaccinated Cohort (mTVC) of ZOSTER-064. The Z-064 mTVC excluded subjects in the Z-064 TVC who were not administered the second vaccination or who developed a confirmed case of Herpes Zoster (HZ) prior to 1 month after the second vaccination.
Incidence rate (IR) of confirmed Herpes zoster (HZ) cases with 95% Confidence Interval (CI) calculated as the number of cases per 1000 person-years : numerator = number of confirmed HZ cases reported during the follow-up (FU) period at risk; denominator = total Person-years at risk, i.e. sum of FU periods at risk expressed in years until first confirmed HZ cases or occurrence of treatment for relapse. A suspected HZ case defined as (1) new rash characteristic of HZ (e.g., unilateral, dermatomal and accompanied by pain broadly defined to include allodynia, pruritus or other sensations), or vesicular rash suggestive of Varicella Zoster Virus (VZV) infection regardless of the distribution, and no alternative diagnosis; or (2) clinical presentation and specific laboratory findings suggestive of VZV infection in the absence of HZ or VZV rash. A suspected case of HZ was confirmed either by PCR or by the HZ Ascertainment Committee (HZAC), consisting of physicians with HZ expertise.
Outcome measures
| Measure |
Overall Group
n=5545 Participants
Adults aged ≥50 years of age in the Zoster-064 TVC who received herpes zoster subunit (HZ/su) vaccine or Placebo in Zoster-006/022 study
|
Non-Frail-Placebo
n=5551 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as non-frail.
|
Pre-Frail-HZ/su
n=5738 Participants
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were categorized as pre-frail.
|
Pre-Frail-Placebo
n=5969 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as pre-frail.
|
Frail-HZ/su
n=1449 Participants
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were categorized as frail.
|
Frail-Placebo
n=1348 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as frail.
|
Unknown-HZ/su
n=53 Participants
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were not assigned a frailty category.
|
Unknown-Placebo
n=62 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were not assigned a frailty category.
|
|---|---|---|---|---|---|---|---|---|
|
Incidence Rate (Per 1000 Person-years) of Confirmed Herpes Zoster (HZ) Cases, by Frailty Status
|
0.4 Cases per 1000 person-year
|
8.8 Cases per 1000 person-year
|
0.8 Cases per 1000 person-year
|
8.6 Cases per 1000 person-year
|
1.0 Cases per 1000 person-year
|
9.9 Cases per 1000 person-year
|
0.0 Cases per 1000 person-year
|
25.8 Cases per 1000 person-year
|
SECONDARY outcome
Timeframe: During the entire study period (3 to 5 year period following Day 0)Population: Analysis was performed on all subjects in the Modified Total Vaccinated Cohort (mTVC) of ZOSTER-064. The Z-064 mTVC excluded subjects in the Z-064 TVC who were not administered the second vaccination or who developed a confirmed case of Herpes Zoster (HZ) prior to 1 month after the second vaccination.
Zoster Brief Pain Inventory (ZBPI) Burden of Illness (BOI) score was calculated as the sum of the ZBPI worst pain scores for all subjects in the group divided by the total follow-up time (Person-years). HZ Burden of Illness score for subjects was calculated from the Zoster Brief Pain Inventory (ZBPI), for each confirmed HZ cases responding to the "worst pain" question in both ZOSTER-006 and ZOSTER-022, and defined as the area under the curve of confirmed HZ-associated pain plotted against time during the 182-day period after the onset of the case. Subjects who developed HZ presented "burden-of-illness" scores ranging from 0 up to, theoretically, 1820. A score of 0 is recorded for subjects in whom HZ did not develop during the study period. Subjects who had a confirmed Zoster episode but who did not have at least 1 ZBPI assessment were excluded from the analysis.
Outcome measures
| Measure |
Overall Group
n=5545 Participants
Adults aged ≥50 years of age in the Zoster-064 TVC who received herpes zoster subunit (HZ/su) vaccine or Placebo in Zoster-006/022 study
|
Non-Frail-Placebo
n=5550 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as non-frail.
|
Pre-Frail-HZ/su
n=5738 Participants
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were categorized as pre-frail.
|
Pre-Frail-Placebo
n=5968 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as pre-frail.
|
Frail-HZ/su
n=1449 Participants
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were categorized as frail.
|
Frail-Placebo
n=1348 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as frail.
|
Unknown-HZ/su
n=53 Participants
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were not assigned a frailty category.
|
Unknown-Placebo
n=60 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were not assigned a frailty category.
|
|---|---|---|---|---|---|---|---|---|
|
Herpes Zoster Burden of Illness Score, by Frailty Status
|
0.017 Score per subject-year
|
1.173 Score per subject-year
|
0.108 Score per subject-year
|
1.475 Score per subject-year
|
0.345 Score per subject-year
|
2.330 Score per subject-year
|
0.000 Score per subject-year
|
3.303 Score per subject-year
|
SECONDARY outcome
Timeframe: Within 7 days (Days 0-6) after each vaccinationPopulation: Analysis was performed on all subjects in the Zoster-064 TVC diary card subset for analysis of reactogenicity. Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
Outcome measures
| Measure |
Overall Group
n=2007 Participants
Adults aged ≥50 years of age in the Zoster-064 TVC who received herpes zoster subunit (HZ/su) vaccine or Placebo in Zoster-006/022 study
|
Non-Frail-Placebo
n=2034 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as non-frail.
|
Pre-Frail-HZ/su
n=1977 Participants
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were categorized as pre-frail.
|
Pre-Frail-Placebo
n=1964 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as pre-frail.
|
Frail-HZ/su
n=489 Participants
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were categorized as frail.
|
Frail-Placebo
n=468 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as frail.
|
Unknown-HZ/su
n=21 Participants
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were not assigned a frailty category.
|
Unknown-Placebo
n=17 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were not assigned a frailty category.
|
|---|---|---|---|---|---|---|---|---|
|
Number of Subjects With Any and Grade 3 Solicited Local Symptoms, by Frailty Status
Any Pain
|
1655 Participants
|
209 Participants
|
1494 Participants
|
211 Participants
|
322 Participants
|
51 Participants
|
17 Participants
|
1 Participants
|
|
Number of Subjects With Any and Grade 3 Solicited Local Symptoms, by Frailty Status
Grade 3 Pain
|
115 Participants
|
4 Participants
|
125 Participants
|
6 Participants
|
38 Participants
|
5 Participants
|
1 Participants
|
0 Participants
|
|
Number of Subjects With Any and Grade 3 Solicited Local Symptoms, by Frailty Status
Any Redness
|
805 Participants
|
25 Participants
|
734 Participants
|
28 Participants
|
160 Participants
|
2 Participants
|
11 Participants
|
0 Participants
|
|
Number of Subjects With Any and Grade 3 Solicited Local Symptoms, by Frailty Status
Grade 3 Redness
|
75 Participants
|
0 Participants
|
46 Participants
|
0 Participants
|
12 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Subjects With Any and Grade 3 Solicited Local Symptoms, by Frailty Status
Any Swelling
|
545 Participants
|
18 Participants
|
497 Participants
|
22 Participants
|
107 Participants
|
3 Participants
|
6 Participants
|
1 Participants
|
|
Number of Subjects With Any and Grade 3 Solicited Local Symptoms, by Frailty Status
Grade 3 Swelling
|
24 Participants
|
0 Participants
|
19 Participants
|
0 Participants
|
2 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: Within 7 days (Days 0-6) after each vaccinationPopulation: Analysis was performed on all subjects in the Zoster-064 TVC diary card subset for analysis of reactogenicity. Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
Assessed solicited general symptoms were, fatigue, fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\], headache, myalgia, shivering and gastro-intestinal (GI) symptoms(nausea, vomiting, diarrhoea and/or abdominal pain) Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
Outcome measures
| Measure |
Overall Group
n=2007 Participants
Adults aged ≥50 years of age in the Zoster-064 TVC who received herpes zoster subunit (HZ/su) vaccine or Placebo in Zoster-006/022 study
|
Non-Frail-Placebo
n=2034 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as non-frail.
|
Pre-Frail-HZ/su
n=1971 Participants
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were categorized as pre-frail.
|
Pre-Frail-Placebo
n=1964 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as pre-frail.
|
Frail-HZ/su
n=488 Participants
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were categorized as frail.
|
Frail-Placebo
n=468 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as frail.
|
Unknown-HZ/su
n=21 Participants
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were not assigned a frailty category.
|
Unknown-Placebo
n=18 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were not assigned a frailty category.
|
|---|---|---|---|---|---|---|---|---|
|
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms, by Frailty Status
Related Myalgia
|
864 Participants
|
153 Participants
|
730 Participants
|
172 Participants
|
148 Participants
|
47 Participants
|
4 Participants
|
2 Participants
|
|
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms, by Frailty Status
Any Fatigue
|
951 Participants
|
301 Participants
|
848 Participants
|
339 Participants
|
164 Participants
|
96 Participants
|
5 Participants
|
4 Participants
|
|
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms, by Frailty Status
Grade 3 Fatigue
|
114 Participants
|
15 Participants
|
93 Participants
|
17 Participants
|
22 Participants
|
8 Participants
|
0 Participants
|
0 Participants
|
|
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms, by Frailty Status
Related Fatigue
|
848 Participants
|
233 Participants
|
715 Participants
|
231 Participants
|
139 Participants
|
54 Participants
|
5 Participants
|
4 Participants
|
|
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms, by Frailty Status
Any Gastrointestinal symptoms
|
369 Participants
|
157 Participants
|
325 Participants
|
166 Participants
|
65 Participants
|
56 Participants
|
2 Participants
|
2 Participants
|
|
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms, by Frailty Status
Grade 3 Gastrointestinal symptoms
|
26 Participants
|
11 Participants
|
28 Participants
|
8 Participants
|
6 Participants
|
5 Participants
|
0 Participants
|
0 Participants
|
|
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms, by Frailty Status
Related Gastrointestinal symptoms
|
298 Participants
|
88 Participants
|
229 Participants
|
86 Participants
|
44 Participants
|
26 Participants
|
0 Participants
|
2 Participants
|
|
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms, by Frailty Status
Any Headache
|
838 Participants
|
287 Participants
|
676 Participants
|
311 Participants
|
147 Participants
|
89 Participants
|
6 Participants
|
3 Participants
|
|
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms, by Frailty Status
Grade 3 Headache
|
74 Participants
|
8 Participants
|
53 Participants
|
12 Participants
|
17 Participants
|
10 Participants
|
0 Participants
|
0 Participants
|
|
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms, by Frailty Status
Related Headache
|
735 Participants
|
202 Participants
|
582 Participants
|
198 Participants
|
122 Participants
|
59 Participants
|
5 Participants
|
3 Participants
|
|
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms, by Frailty Status
Any Myalgia
|
952 Participants
|
209 Participants
|
828 Participants
|
225 Participants
|
173 Participants
|
75 Participants
|
5 Participants
|
2 Participants
|
|
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms, by Frailty Status
Grade 3 Myalgia
|
100 Participants
|
8 Participants
|
89 Participants
|
8 Participants
|
28 Participants
|
12 Participants
|
0 Participants
|
0 Participants
|
|
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms, by Frailty Status
Any Shivering
|
623 Participants
|
111 Participants
|
459 Participants
|
107 Participants
|
86 Participants
|
41 Participants
|
3 Participants
|
3 Participants
|
|
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms, by Frailty Status
Grade 3 Shivering
|
103 Participants
|
4 Participants
|
57 Participants
|
6 Participants
|
18 Participants
|
2 Participants
|
0 Participants
|
0 Participants
|
|
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms, by Frailty Status
Related Shivering
|
559 Participants
|
80 Participants
|
398 Participants
|
74 Participants
|
74 Participants
|
22 Participants
|
3 Participants
|
3 Participants
|
|
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms, by Frailty Status
Any Fever
|
465 Participants
|
52 Participants
|
368 Participants
|
55 Participants
|
70 Participants
|
19 Participants
|
1 Participants
|
0 Participants
|
|
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms, by Frailty Status
Grade 3 Fever
|
6 Participants
|
4 Participants
|
5 Participants
|
3 Participants
|
2 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms, by Frailty Status
Related Fever
|
419 Participants
|
35 Participants
|
316 Participants
|
29 Participants
|
57 Participants
|
8 Participants
|
1 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: Within 30 days (Days 0 - 29) after each vaccinationPopulation: Analysis was performed on all subjects included in the Zoster-064 TVC. Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
An unsolicited AE covered any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
Outcome measures
| Measure |
Overall Group
n=5784 Participants
Adults aged ≥50 years of age in the Zoster-064 TVC who received herpes zoster subunit (HZ/su) vaccine or Placebo in Zoster-006/022 study
|
Non-Frail-Placebo
n=5734 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as non-frail.
|
Pre-Frail-HZ/su
n=6071 Participants
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were categorized as pre-frail.
|
Pre-Frail-Placebo
n=6219 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as pre-frail.
|
Frail-HZ/su
n=1573 Participants
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were categorized as frail.
|
Frail-Placebo
n=1464 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as frail.
|
Unknown-HZ/su
n=59 Participants
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were not assigned a frailty category.
|
Unknown-Placebo
n=72 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were not assigned a frailty category.
|
|---|---|---|---|---|---|---|---|---|
|
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs), by Frailty Status
Any AE
|
2984 Participants
|
1696 Participants
|
3019 Participants
|
2034 Participants
|
754 Participants
|
520 Participants
|
23 Participants
|
22 Participants
|
|
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs), by Frailty Status
Grade 3 AE
|
429 Participants
|
182 Participants
|
429 Participants
|
242 Participants
|
134 Participants
|
80 Participants
|
5 Participants
|
5 Participants
|
|
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs), by Frailty Status
Related AE
|
2223 Participants
|
386 Participants
|
1962 Participants
|
420 Participants
|
449 Participants
|
91 Participants
|
16 Participants
|
6 Participants
|
SECONDARY outcome
Timeframe: From Month 0 to Month 14Population: Analysis was performed on all subjects included in the Zoster-064 TVC. Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Related SAEs were those considered vaccine-related by the investigator.
Outcome measures
| Measure |
Overall Group
n=5784 Participants
Adults aged ≥50 years of age in the Zoster-064 TVC who received herpes zoster subunit (HZ/su) vaccine or Placebo in Zoster-006/022 study
|
Non-Frail-Placebo
n=5734 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as non-frail.
|
Pre-Frail-HZ/su
n=6071 Participants
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were categorized as pre-frail.
|
Pre-Frail-Placebo
n=6219 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as pre-frail.
|
Frail-HZ/su
n=1573 Participants
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were categorized as frail.
|
Frail-Placebo
n=1464 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as frail.
|
Unknown-HZ/su
n=59 Participants
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were not assigned a frailty category.
|
Unknown-Placebo
n=72 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were not assigned a frailty category.
|
|---|---|---|---|---|---|---|---|---|
|
Number of Subjects With Any and Related Serious Adverse Events (SAEs), by Frailty Status
Any SAEs
|
357 Participants
|
328 Participants
|
697 Participants
|
751 Participants
|
293 Participants
|
332 Participants
|
8 Participants
|
10 Participants
|
|
Number of Subjects With Any and Related Serious Adverse Events (SAEs), by Frailty Status
Related SAEs
|
6 Participants
|
3 Participants
|
6 Participants
|
9 Participants
|
2 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: During the entire study period (3 to 5 year period following Day 0)Population: Analysis was performed on all subjects included in the Zoster-064 TVC. Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Related SAEs throughout the entire study period by frailty status were reported for SAEs considered related to study participation or to a concurrent GSK medication/vaccine.
Outcome measures
| Measure |
Overall Group
n=5784 Participants
Adults aged ≥50 years of age in the Zoster-064 TVC who received herpes zoster subunit (HZ/su) vaccine or Placebo in Zoster-006/022 study
|
Non-Frail-Placebo
n=5734 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as non-frail.
|
Pre-Frail-HZ/su
n=6071 Participants
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were categorized as pre-frail.
|
Pre-Frail-Placebo
n=6219 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as pre-frail.
|
Frail-HZ/su
n=1573 Participants
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were categorized as frail.
|
Frail-Placebo
n=1464 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as frail.
|
Unknown-HZ/su
n=59 Participants
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were not assigned a frailty category.
|
Unknown-Placebo
n=72 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were not assigned a frailty category.
|
|---|---|---|---|---|---|---|---|---|
|
Number of Subjects With SAEs Related to Study Participation or to a Concurrent GSK Medication/Vaccine, by Frailty Status
|
14 Participants
|
16 Participants
|
55 Participants
|
49 Participants
|
24 Participants
|
31 Participants
|
0 Participants
|
2 Participants
|
SECONDARY outcome
Timeframe: During the entire study period (3 to 5 year period following Day 0)Population: Analysis was performed on all subjects included in the Zoster-064 TVC. Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
Serious adverse events (SAEs) assessed include medical occurrences that result in death.
Outcome measures
| Measure |
Overall Group
n=5784 Participants
Adults aged ≥50 years of age in the Zoster-064 TVC who received herpes zoster subunit (HZ/su) vaccine or Placebo in Zoster-006/022 study
|
Non-Frail-Placebo
n=5734 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as non-frail.
|
Pre-Frail-HZ/su
n=6071 Participants
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were categorized as pre-frail.
|
Pre-Frail-Placebo
n=6219 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as pre-frail.
|
Frail-HZ/su
n=1573 Participants
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were categorized as frail.
|
Frail-Placebo
n=1464 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as frail.
|
Unknown-HZ/su
n=59 Participants
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were not assigned a frailty category.
|
Unknown-Placebo
n=72 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were not assigned a frailty category.
|
|---|---|---|---|---|---|---|---|---|
|
Number of Subjects With Any Fatal Serious Adverse Events (SAEs), by Frailty Status
|
124 Participants
|
109 Participants
|
299 Participants
|
343 Participants
|
174 Participants
|
182 Participants
|
2 Participants
|
6 Participants
|
SECONDARY outcome
Timeframe: During the entire study period (3 to 5 year period following Day 0)Population: Analysis was performed on all subjects included in the Zoster-064 TVC. Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Related = pIMDs assessed by the investigator as related to the vaccination.
Outcome measures
| Measure |
Overall Group
n=5784 Participants
Adults aged ≥50 years of age in the Zoster-064 TVC who received herpes zoster subunit (HZ/su) vaccine or Placebo in Zoster-006/022 study
|
Non-Frail-Placebo
n=5734 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as non-frail.
|
Pre-Frail-HZ/su
n=6071 Participants
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were categorized as pre-frail.
|
Pre-Frail-Placebo
n=6219 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as pre-frail.
|
Frail-HZ/su
n=1573 Participants
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were categorized as frail.
|
Frail-Placebo
n=1464 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as frail.
|
Unknown-HZ/su
n=59 Participants
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were not assigned a frailty category.
|
Unknown-Placebo
n=72 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were not assigned a frailty category.
|
|---|---|---|---|---|---|---|---|---|
|
Number of Subjects With Any and Related Potential Immune-mediated Diseases (pIMDs), by Frailty Status
Any pIMDs
|
74 Participants
|
69 Participants
|
76 Participants
|
90 Participants
|
15 Participants
|
27 Participants
|
1 Participants
|
0 Participants
|
|
Number of Subjects With Any and Related Potential Immune-mediated Diseases (pIMDs), by Frailty Status
Related pIMDs
|
4 Participants
|
7 Participants
|
9 Participants
|
6 Participants
|
2 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: Pre-vaccination at Month 0, and post second dose at Months 3, 14, 26 and 38Population: Analysis was performed on a subset of subjects in Z-064 According to Protocol (ATP) cohort for immunogenicity-humoral (i.e. those among the Z-064 TVC, who met all eligibility criteria, complied with procedures and intervals for analysis,with no elimination criteria during Z-006/022 studies,and for whom data concerning immunogenicity were available)
Anti-gE Ab concentrations as determined by Enzyme-linked Immunosorbent Assay (ELISA), in a subset of subjects. The assay cut-off is 97 milli-international units (mIU)/mL.
Outcome measures
| Measure |
Overall Group
n=603 Participants
Adults aged ≥50 years of age in the Zoster-064 TVC who received herpes zoster subunit (HZ/su) vaccine or Placebo in Zoster-006/022 study
|
Non-Frail-Placebo
n=606 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as non-frail.
|
Pre-Frail-HZ/su
n=655 Participants
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were categorized as pre-frail.
|
Pre-Frail-Placebo
n=697 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as pre-frail.
|
Frail-HZ/su
n=138 Participants
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were categorized as frail.
|
Frail-Placebo
n=125 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as frail.
|
Unknown-HZ/su
n=4 Participants
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were not assigned a frailty category.
|
Unknown-Placebo
n=4 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were not assigned a frailty category.
|
|---|---|---|---|---|---|---|---|---|
|
Anti-glycoprotein E (Anti-gE) Antibody (Ab) Concentrations, by Frailty Status, in a Subset of Subjects
Anti-gE Ab at Month 0
|
1251.6 mIU/mL
Interval 1151.7 to 1360.3
|
1389.1 mIU/mL
Interval 1286.6 to 1499.8
|
1363.0 mIU/mL
Interval 1262.1 to 1471.9
|
1325.4 mIU/mL
Interval 1227.0 to 1431.7
|
1450.8 mIU/mL
Interval 1230.9 to 1710.1
|
1457.7 mIU/mL
Interval 1213.6 to 1750.8
|
1172.9 mIU/mL
Interval 389.0 to 3536.5
|
836.2 mIU/mL
Interval 157.6 to 4434.9
|
|
Anti-glycoprotein E (Anti-gE) Antibody (Ab) Concentrations, by Frailty Status, in a Subset of Subjects
Anti-gE antibody at Month 3
|
53120.8 mIU/mL
Interval 50229.2 to 56178.8
|
1314.6 mIU/mL
Interval 1211.8 to 1426.2
|
52514.0 mIU/mL
Interval 49937.0 to 55224.0
|
1266.9 mIU/mL
Interval 1171.6 to 1369.9
|
44914.9 mIU/mL
Interval 39734.6 to 50770.6
|
1310.8 mIU/mL
Interval 1089.8 to 1576.7
|
34703.5 mIU/mL
Interval 18272.8 to 65908.6
|
854.8 mIU/mL
Interval 119.2 to 6132.2
|
|
Anti-glycoprotein E (Anti-gE) Antibody (Ab) Concentrations, by Frailty Status, in a Subset of Subjects
Anti-gE antibody at Month 14
|
18628.2 mIU/mL
Interval 17477.6 to 19854.6
|
1272.4 mIU/mL
Interval 1174.4 to 1378.5
|
16689.7 mIU/mL
Interval 15739.5 to 17697.2
|
1224.7 mIU/mL
Interval 1129.9 to 1327.4
|
13405.4 mIU/mL
Interval 11701.3 to 15357.7
|
1337.8 mIU/mL
Interval 1089.7 to 1642.4
|
9834.3 mIU/mL
Interval 3469.9 to 27871.7
|
888.2 mIU/mL
Interval 270.6 to 2914.9
|
|
Anti-glycoprotein E (Anti-gE) Antibody (Ab) Concentrations, by Frailty Status, in a Subset of Subjects
Anti-gE antibody at Month 26
|
14502.0 mIU/mL
Interval 13610.9 to 15451.4
|
1355.5 mIU/mL
Interval 1253.2 to 1466.1
|
13344.2 mIU/mL
Interval 12592.6 to 14140.6
|
1320.2 mIU/mL
Interval 1219.1 to 1429.6
|
11060.6 mIU/mL
Interval 9689.0 to 12626.3
|
1431.4 mIU/mL
Interval 1156.2 to 1772.2
|
5278.7 mIU/mL
Interval 1248.8 to 22313.6
|
712.8 mIU/mL
Interval 143.6 to 3538.1
|
|
Anti-glycoprotein E (Anti-gE) Antibody (Ab) Concentrations, by Frailty Status, in a Subset of Subjects
Anti-gE antibody at Month 38
|
12505.4 mIU/mL
Interval 11695.1 to 13371.8
|
1304.3 mIU/mL
Interval 1203.5 to 1413.5
|
11099.9 mIU/mL
Interval 10458.8 to 11780.4
|
1274.3 mIU/mL
Interval 1171.4 to 1386.2
|
8694.8 mIU/mL
Interval 7612.1 to 9931.6
|
1399.1 mIU/mL
Interval 1112.6 to 1759.2
|
5128.7 mIU/mL
Interval 1349.3 to 19494.2
|
614.9 mIU/mL
Interval 64.5 to 5863.9
|
SECONDARY outcome
Timeframe: Pre-vaccination at Month 0, and post second dose at Months 3, 14, 26 and 38Population: Analysis was performed on a subset of subjects in Z-064 According to Protocol (ATP) cohort for immunogenicity-humoral (i.e. those among the Z-064 TVC, who met all eligibility criteria, complied with procedures and intervals for analysis,with no elimination criteria during Z-006/022 studies,and for whom data concerning immunogenicity were available)
Anti-VZV Ab concentrations as determined by Enzyme-linked Immunosorbent Assay (ELISA), in a subset of subjects. The assay cut-off is 25 mIU/mL.
Outcome measures
| Measure |
Overall Group
n=603 Participants
Adults aged ≥50 years of age in the Zoster-064 TVC who received herpes zoster subunit (HZ/su) vaccine or Placebo in Zoster-006/022 study
|
Non-Frail-Placebo
n=594 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as non-frail.
|
Pre-Frail-HZ/su
n=655 Participants
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were categorized as pre-frail.
|
Pre-Frail-Placebo
n=677 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as pre-frail.
|
Frail-HZ/su
n=138 Participants
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were categorized as frail.
|
Frail-Placebo
n=124 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as frail.
|
Unknown-HZ/su
n=4 Participants
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were not assigned a frailty category.
|
Unknown-Placebo
n=4 Participants
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were not assigned a frailty category.
|
|---|---|---|---|---|---|---|---|---|
|
Anti-Varicella Zoster Virus (Anti-VZV) Antibody (Ab) Concentrations, by Frailty Status, in a Subset of Subjects
Anti-VZV antibody at Month 0
|
966.9 mIU/mL
Interval 893.6 to 1046.2
|
1053.3 mIU/mL
Interval 981.8 to 1130.0
|
992.9 mIU/mL
Interval 927.8 to 1062.7
|
1036.9 mIU/mL
Interval 969.7 to 1108.7
|
996.6 mIU/mL
Interval 866.7 to 1146.1
|
1054.7 mIU/mL
Interval 894.9 to 1243.1
|
712.3 mIU/mL
Interval 166.2 to 3052.9
|
553.7 mIU/mL
Interval 63.7 to 4812.0
|
|
Anti-Varicella Zoster Virus (Anti-VZV) Antibody (Ab) Concentrations, by Frailty Status, in a Subset of Subjects
Anti-VZV antibody at Month 3
|
9206.0 mIU/mL
Interval 8731.3 to 9706.5
|
989.8 mIU/mL
Interval 922.5 to 1061.9
|
9468.9 mIU/mL
Interval 9046.7 to 9910.8
|
997.0 mIU/mL
Interval 933.4 to 1065.0
|
8162.4 mIU/mL
Interval 7332.5 to 9086.2
|
904.2 mIU/mL
Interval 764.4 to 1069.4
|
6499.1 mIU/mL
Interval 4054.7 to 10417.1
|
601.7 mIU/mL
Interval 78.7 to 4601.0
|
|
Anti-Varicella Zoster Virus (Anti-VZV) Antibody (Ab) Concentrations, by Frailty Status, in a Subset of Subjects
Anti-VZV antibody at Month 14
|
3791.4 mIU/mL
Interval 3569.3 to 4027.2
|
931.4 mIU/mL
Interval 867.4 to 1000.1
|
3630.9 mIU/mL
Interval 3450.2 to 3821.0
|
945.3 mIU/mL
Interval 883.8 to 1011.0
|
3034.4 mIU/mL
Interval 2719.3 to 3386.1
|
921.9 mIU/mL
Interval 769.0 to 1105.2
|
2175.3 mIU/mL
Interval 1073.6 to 4407.6
|
646.9 mIU/mL
Interval 90.1 to 4646.3
|
|
Anti-Varicella Zoster Virus (Anti-VZV) Antibody (Ab) Concentrations, by Frailty Status, in a Subset of Subjects
Anti-VZV antibody at Month 26
|
3226.8 mIU/mL
Interval 3037.6 to 3427.7
|
986.0 mIU/mL
Interval 918.0 to 1058.9
|
3261.7 mIU/mL
Interval 3094.9 to 3437.5
|
1040.8 mIU/mL
Interval 973.8 to 1112.3
|
2759.4 mIU/mL
Interval 2472.4 to 3079.8
|
1023.0 mIU/mL
Interval 850.1 to 1231.1
|
1909.4 mIU/mL
Interval 839.1 to 4344.8
|
374.7 mIU/mL
Interval 48.9 to 2869.2
|
|
Anti-Varicella Zoster Virus (Anti-VZV) Antibody (Ab) Concentrations, by Frailty Status, in a Subset of Subjects
Anti-VZV antibody at Month 38
|
3111.6 mIU/mL
Interval 2928.2 to 3306.4
|
1029.2 mIU/mL
Interval 958.8 to 1104.8
|
2966.3 mIU/mL
Interval 2813.9 to 3126.9
|
1068.0 mIU/mL
Interval 994.7 to 1146.7
|
2462.1 mIU/mL
Interval 2201.7 to 2753.4
|
1098.1 mIU/mL
Interval 903.3 to 1334.8
|
1928.4 mIU/mL
Interval 857.8 to 4335.2
|
286.3 mIU/mL
Interval 33.3 to 2460.0
|
Adverse Events
Non-Frail-HZ/su
Serious events: 453 serious events
Other events: 2961 other events
Deaths: 124 deaths
Non-Frail-Placebo
Serious events: 413 serious events
Other events: 1668 other events
Deaths: 109 deaths
Pre-Frail-HZ/su
Serious events: 886 serious events
Other events: 2955 other events
Deaths: 299 deaths
Pre-Frail-Placebo
Serious events: 964 serious events
Other events: 1953 other events
Deaths: 343 deaths
Frail-HZ/su
Serious events: 385 serious events
Other events: 730 other events
Deaths: 174 deaths
Frail-Placebo
Serious events: 426 serious events
Other events: 481 other events
Deaths: 182 deaths
Unknown-HZ/su
Serious events: 10 serious events
Other events: 23 other events
Deaths: 2 deaths
Unknown-Placebo
Serious events: 14 serious events
Other events: 22 other events
Deaths: 6 deaths
Serious adverse events
| Measure |
Non-Frail-HZ/su
n=5784 participants at risk
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were categorized as non-frail.
|
Non-Frail-Placebo
n=5734 participants at risk
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as non-frail.
|
Pre-Frail-HZ/su
n=6071 participants at risk
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were categorized as pre-frail.
|
Pre-Frail-Placebo
n=6219 participants at risk
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as pre-frail.
|
Frail-HZ/su
n=1573 participants at risk
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were categorized as frail.
|
Frail-Placebo
n=1464 participants at risk
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as frail.
|
Unknown-HZ/su
n=59 participants at risk
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were not assigned a frailty category.
|
Unknown-Placebo
n=72 participants at risk
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were not assigned a frailty category.
|
|---|---|---|---|---|---|---|---|---|
|
Blood and lymphatic system disorders
Anaemia
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6071 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
9/6219 • Number of events 9 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.34%
5/1464 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Blood and lymphatic system disorders
Disseminated intravascular coagulation
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Blood and lymphatic system disorders
Heparin-induced thrombocytopenia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Blood and lymphatic system disorders
Immune thrombocytopenic purpura
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Blood and lymphatic system disorders
Iron deficiency anaemia
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Blood and lymphatic system disorders
Lymphadenitis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Blood and lymphatic system disorders
Lymphadenopathy
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Blood and lymphatic system disorders
Anaemia vitamin b12 deficiency
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Blood and lymphatic system disorders
Coagulopathy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Blood and lymphatic system disorders
Haemorrhagic anaemia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Blood and lymphatic system disorders
Lymphadenopathy mediastinal
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Blood and lymphatic system disorders
Microcytic anaemia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Blood and lymphatic system disorders
Nephrogenic anaemia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Blood and lymphatic system disorders
Pernicious anaemia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Blood and lymphatic system disorders
Splenic infarction
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.20%
3/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Blood and lymphatic system disorders
Hypersplenism
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Blood and lymphatic system disorders
Hypochromic anaemia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Blood and lymphatic system disorders
Normochromic normocytic anaemia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Blood and lymphatic system disorders
Pancytopenia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Acute coronary syndrome
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6219 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Acute myocardial infarction
|
0.09%
5/5784 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/5734 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.25%
15/6071 • Number of events 16 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.39%
24/6219 • Number of events 24 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.45%
7/1573 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.1%
16/1464 • Number of events 17 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Angina pectoris
|
0.03%
2/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6071 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.45%
7/1573 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.41%
6/1464 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Angina unstable
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6219 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Aortic valve stenosis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Arrhythmia
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.12%
7/6071 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.20%
3/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Arteriosclerosis coronary artery
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Atrial fibrillation
|
0.21%
12/5784 • Number of events 12 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.21%
12/5734 • Number of events 12 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.46%
28/6071 • Number of events 36 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.53%
33/6219 • Number of events 33 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.0%
16/1573 • Number of events 17 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.68%
10/1464 • Number of events 12 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Atrial flutter
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6071 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.41%
6/1464 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Atrioventricular block complete
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Atrioventricular block second degree
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Bradycardia
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.27%
4/1464 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Cardiac arrest
|
0.09%
5/5784 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.25%
15/6071 • Number of events 15 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.26%
16/6219 • Number of events 16 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.51%
8/1573 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.48%
7/1464 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Cardiac failure
|
0.16%
9/5784 • Number of events 9 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/5734 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.61%
37/6071 • Number of events 37 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.69%
43/6219 • Number of events 46 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.5%
23/1573 • Number of events 25 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
2.0%
30/1464 • Number of events 35 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Cardiac failure acute
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Cardiac failure chronic
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Cardiac failure congestive
|
0.07%
4/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.18%
11/6071 • Number of events 11 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.23%
14/6219 • Number of events 16 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.1%
17/1573 • Number of events 17 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
21/1464 • Number of events 23 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Cardiac tamponade
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Cardiac valve disease
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Cardio-respiratory arrest
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.27%
4/1464 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Cardiogenic shock
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Cardiopulmonary failure
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Cardiovascular deconditioning
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Congestive cardiomyopathy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Coronary artery disease
|
0.10%
6/5784 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
8/5734 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.28%
17/6071 • Number of events 18 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.32%
20/6219 • Number of events 20 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.89%
14/1573 • Number of events 14 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.89%
13/1464 • Number of events 15 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
1/59 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Coronary artery insufficiency
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Coronary artery stenosis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Extrasystoles
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Left ventricular hypertrophy
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Mitral valve incompetence
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Mitral valve prolapse
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Myocardial infarction
|
0.14%
8/5784 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.30%
17/5734 • Number of events 17 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.58%
35/6071 • Number of events 35 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.53%
33/6219 • Number of events 33 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.1%
18/1573 • Number of events 19 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.3%
19/1464 • Number of events 19 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Myocardial ischaemia
|
0.07%
4/5784 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.12%
7/6071 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.32%
20/6219 • Number of events 20 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.34%
5/1464 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Palpitations
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Sinus node dysfunction
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Tachycardia
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Ventricular extrasystoles
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Ventricular fibrillation
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Acute left ventricular failure
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Aortic valve disease
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Aortic valve incompetence
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Atrial tachycardia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Atrioventricular block
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Atrioventricular block first degree
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Bradyarrhythmia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Cardiomegaly
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Cardiomyopathy alcoholic
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Cardiovascular insufficiency
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Coronary artery occlusion
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Diastolic dysfunction
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Heart valve incompetence
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Hypertensive heart disease
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Intracardiac thrombus
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Ischaemic cardiomyopathy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Left ventricular failure
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Pericardial effusion
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Pericarditis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Right ventricular failure
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Sinus arrest
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Stress cardiomyopathy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Supraventricular tachycardia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Tricuspid valve incompetence
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Ventricular tachycardia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
1/59 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Arrhythmia supraventricular
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Cardiac disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Cardiomyopathy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Chronotropic incompetence
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Cor pulmonale
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Mitral valve stenosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Sinus tachycardia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Ventricular arrhythmia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Congenital, familial and genetic disorders
Congenital cystic kidney disease
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Congenital, familial and genetic disorders
Hydrocele
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Congenital, familial and genetic disorders
Odontogenic cyst
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Congenital, familial and genetic disorders
Pyloric stenosis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Congenital, familial and genetic disorders
Cystic fibrosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Congenital, familial and genetic disorders
Hypertrophic cardiomyopathy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Congenital, familial and genetic disorders
Renal dysplasia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Ear and labyrinth disorders
Deafness neurosensory
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Ear and labyrinth disorders
Motion sickness
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Ear and labyrinth disorders
Sudden hearing loss
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Gastrooesophageal reflux disease
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Ear and labyrinth disorders
Vertigo
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Ear and labyrinth disorders
Vertigo positional
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Ear and labyrinth disorders
Vestibular disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Endocrine disorders
Basedow's disease
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Endocrine disorders
Goitre
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Endocrine disorders
Hyperthyroidism
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Endocrine disorders
Autoimmune thyroiditis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Endocrine disorders
Cushingoid
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Endocrine disorders
Hyperparathyroidism primary
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Endocrine disorders
Hypothyroidism
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Endocrine disorders
Hypopituitarism
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Endocrine disorders
Thyroiditis subacute
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Amaurosis fugax
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Cataract
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.12%
7/6071 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.11%
7/6219 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Macular cyst
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Macular hole
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Retinal detachment
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/5734 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Retinal tear
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Abdominal adhesions
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Abdominal strangulated hernia
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Colitis ischaemic
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.20%
3/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Crohn's disease
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Diverticulum
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Gastric ulcer
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.20%
3/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Gastric ulcer haemorrhage
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Gastritis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6071 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
8/6219 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Gastrointestinal polyp haemorrhage
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Haemorrhoidal haemorrhage
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Haemorrhoids
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Ileus
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.27%
4/1464 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Incarcerated inguinal hernia
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Inguinal hernia
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.12%
7/5734 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.11%
7/6219 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Intestinal ischaemia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Intestinal obstruction
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6071 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6219 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Intestinal perforation
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Intestinal polyp
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Irritable bowel syndrome
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Large intestinal obstruction
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Large intestine perforation
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Large intestine polyp
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/5734 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Adverse drug reaction
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Mesenteric artery thrombosis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Oesophagitis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Pancreatitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6071 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Pancreatitis acute
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.11%
7/6219 • Number of events 9 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.25%
4/1573 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Pancreatitis necrotising
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Peptic ulcer perforation
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Peritoneal cyst
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Pneumoperitoneum
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Rectal haemorrhage
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Rectal perforation
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Rectal polyp
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Small intestinal obstruction
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Thrombosis mesenteric vessel
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Upper gastrointestinal haemorrhage
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Volvulus
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Administration site erythema
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Administration site pain
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Chest discomfort
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Chest pain
|
0.10%
6/5784 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.26%
16/6071 • Number of events 16 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.32%
20/6219 • Number of events 20 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.32%
5/1573 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.20%
3/1464 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Chills
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Cyst
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Death
|
0.09%
5/5784 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
8/5734 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.23%
14/6071 • Number of events 14 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.32%
20/6219 • Number of events 20 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.51%
8/1573 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.96%
14/1464 • Number of events 14 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Drowning
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Incarcerated hernia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Influenza like illness
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Multi-organ failure
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.15%
9/6071 • Number of events 9 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.48%
7/1464 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Non-cardiac chest pain
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Pyrexia
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Strangulated hernia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Sudden cardiac death
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Sudden death
|
0.07%
4/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
8/6071 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.25%
4/1573 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.20%
3/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Systemic inflammatory response syndrome
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Thrombosis in device
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Choroidal effusion
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Diplopia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Eyelid ptosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Glaucoma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Iridocele
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Lens dislocation
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Neovascular age-related macular degeneration
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Ocular hypertension
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Ocular vascular disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Optic ischaemic neuropathy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Retinal artery occlusion
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Retinal degeneration
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Retinal haemorrhage
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Vitreous haemorrhage
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Age-related macular degeneration
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Iritis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Abdominal hernia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Anal prolapse
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Ascites
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Autoimmune pancreatitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Barrett's oesophagus
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Chronic gastritis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Colitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Diaphragmatic hernia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Diverticulum intestinal
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Duodenal ulcer
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Duodenal ulcer haemorrhage
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Duodenal ulcer perforation
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Duodenitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Enteritis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Faecal incontinence
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Functional gastrointestinal disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Gastric perforation
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Gastric polyps
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Gastric ulcer perforation
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Gastritis alcoholic
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Gastritis haemorrhagic
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Gastrointestinal angiodysplasia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Gastrointestinal haemorrhage
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6071 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Gingival disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Haematochezia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Hiatus hernia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Incarcerated umbilical hernia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Intestinal congestion
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Intestinal infarction
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Mallory-weiss syndrome
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Mesenteric artery embolism
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Mesenteritis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Mouth ulceration
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Oesophageal haemorrhage
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Oesophageal spasm
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Oesophageal ulcer
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Oesophageal varices haemorrhage
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Pancreatic cyst
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Pancreatic fistula
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Peptic ulcer
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Peptic ulcer haemorrhage
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Periodontal disease
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Proctitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Retroperitoneal haemorrhage
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Salivary gland calculus
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Splenic artery aneurysm
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Subileus
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Umbilical hernia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Abdominal discomfort
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Diaphragmatic hernia, obstructive
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Diverticulum intestinal haemorrhagic
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Enterovesical fistula
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Gastric haemorrhage
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Inguinal hernia strangulated
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Melaena
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Oesophageal ulcer haemorrhage
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Pancreatic disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Peritoneal haemorrhage
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Portal hypertensive gastropathy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Accidental death
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Asthenia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Device deposit issue
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Device dislocation
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Device failure
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Device occlusion
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Fatigue
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
General physical health deterioration
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Gravitational oedema
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Ill-defined disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Impaired healing
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Inflammation
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Malaise
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Oedema peripheral
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Polyp
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Cardiac death
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Device battery issue
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Device leakage
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Drug withdrawal syndrome
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Generalised oedema
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Hernia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Organ failure
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Pain
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Peripheral swelling
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Hepatobiliary disorders
Bile duct stenosis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Hepatobiliary disorders
Bile duct stone
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Hepatobiliary disorders
Cholangitis
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Hepatobiliary disorders
Cholecystitis
|
0.07%
4/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/5734 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.12%
7/6071 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
12/6219 • Number of events 14 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.27%
4/1464 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Hepatobiliary disorders
Cholecystitis acute
|
0.07%
4/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6071 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Hepatobiliary disorders
Cholelithiasis
|
0.14%
8/5784 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/5734 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
8/6071 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.21%
13/6219 • Number of events 13 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.27%
4/1464 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Hepatobiliary disorders
Gallbladder polyp
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Hepatobiliary disorders
Hepatic cirrhosis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Hepatobiliary disorders
Hepatic failure
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Hepatobiliary disorders
Hepatotoxicity
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Hepatobiliary disorders
Jaundice cholestatic
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Hepatobiliary disorders
Biliary colic
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Hepatobiliary disorders
Cholangitis acute
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Hepatobiliary disorders
Cirrhosis alcoholic
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Hepatobiliary disorders
Drug-induced liver injury
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Hepatobiliary disorders
Fatty liver alcoholic
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Hepatobiliary disorders
Gallbladder perforation
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Hepatobiliary disorders
Hepatitis alcoholic
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Hepatobiliary disorders
Acute hepatic failure
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Hepatobiliary disorders
Bile duct obstruction
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Hepatobiliary disorders
Biliary dilatation
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Hepatobiliary disorders
Cholecystitis chronic
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Hepatobiliary disorders
Cholestasis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Hepatobiliary disorders
Hepatic function abnormal
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Hepatobiliary disorders
Hepatitis acute
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Hepatobiliary disorders
Ischaemic hepatitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Immune system disorders
Anaphylactic reaction
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
1/59 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Immune system disorders
Drug hypersensitivity
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Immune system disorders
Hypersensitivity
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Immune system disorders
Sarcoidosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Immune system disorders
Allergic granulomatous angiitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Immune system disorders
Amyloidosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Abdominal infection
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Abscess neck
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Anal abscess
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Appendicitis
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/5734 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6071 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Appendicitis perforated
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Arthritis bacterial
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Arthritis infective
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Bacterial sepsis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Breast abscess
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Bronchitis
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6071 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.25%
4/1573 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.55%
8/1464 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Bronchitis bacterial
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Bronchopneumonia
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Cellulitis
|
0.09%
5/5784 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.12%
7/6071 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
8/6219 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.41%
6/1464 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Cellulitis orbital
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Cellulitis streptococcal
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Endocarditis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Cholecystitis infective
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Clostridium difficile colitis
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Clostridium difficile infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Cystitis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Dengue fever
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Diverticulitis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
9/6219 • Number of events 10 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Empyema
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Endometritis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Erysipelas
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Escherichia sepsis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Gastroenteritis
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6071 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.11%
7/6219 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Gastroenteritis caliciviral
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Gastroenteritis norovirus
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Gastroenteritis viral
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Herpes zoster oticus
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Infected dermal cyst
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Infective exacerbation of chronic obstructive airways disease
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Intestinal gangrene
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Klebsiella sepsis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Liver abscess
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Localised infection
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Nasal abscess
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Nasopharyngitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Necrotising fasciitis streptococcal
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Neuroborreliosis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Oesophageal candidiasis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Oropharyngeal candidiasis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Osteomyelitis
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Peritonitis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Peritonsillar abscess
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Pharyngotonsillitis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Pneumonia
|
0.35%
20/5784 • Number of events 20 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.30%
17/5734 • Number of events 17 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.91%
55/6071 • Number of events 57 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.80%
50/6219 • Number of events 52 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
27/1573 • Number of events 29 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
2.2%
32/1464 • Number of events 36 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
3.4%
2/59 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
2.8%
2/72 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Pneumonia mycoplasmal
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Pneumonia streptococcal
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Post procedural infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Postoperative wound infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Purulence
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Pyelonephritis
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Pyelonephritis acute
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Respiratory tract infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Sepsis
|
0.10%
6/5784 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/5734 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
8/6071 • Number of events 9 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.23%
14/6219 • Number of events 14 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.0%
16/1573 • Number of events 16 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.68%
10/1464 • Number of events 11 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Septic shock
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/5734 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.11%
7/6219 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.32%
5/1573 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.27%
4/1464 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Serratia infection
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Shigella infection
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Sinusitis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Staphylococcal infection
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Staphylococcal osteomyelitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Staphylococcal sepsis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Subcutaneous abscess
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Superinfection
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Tonsillitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Tuberculosis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Tularaemia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Upper respiratory tract infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Upper respiratory tract infection bacterial
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Urinary tract infection
|
0.12%
7/5784 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/5734 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.30%
18/6071 • Number of events 19 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.32%
20/6219 • Number of events 21 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.70%
11/1573 • Number of events 14 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.55%
8/1464 • Number of events 10 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
2.8%
2/72 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Urosepsis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.34%
5/1464 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Vestibular neuronitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/5734 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Visceral leishmaniasis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Wound infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Wound infection pseudomonas
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Abdominal abscess
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Acarodermatitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Alcaligenes infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Anorectal cellulitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Appendiceal abscess
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Arteriosclerotic gangrene
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Bacteraemia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Biliary sepsis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Biliary tract infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Candida infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Candida sepsis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Catheter site infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Cavernous sinus thrombosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Clostridium bacteraemia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Colonic abscess
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Cystitis klebsiella
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Diabetic foot infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Diabetic gangrene
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Encephalitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Encephalitis viral
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Encephalomyelitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Gangrene
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Gastroenteritis clostridial
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Gastroenteritis salmonella
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Gastrointestinal infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Helicobacter gastritis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Hepatitis a
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Herpes zoster
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
2.8%
2/72 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Incision site infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Infectious colitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Influenza
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Kidney infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Labyrinthitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Lobar pneumonia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.41%
6/1464 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Lower respiratory tract infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.27%
4/1464 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Lung abscess
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Lung infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Necrotising fasciitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Orchitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Osteomyelitis chronic
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Otitis media chronic
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Pancreatic abscess
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Periodontitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Pertussis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Pharyngitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Pneumonia bacterial
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Pneumonia klebsiella
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Pneumonia pneumococcal
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Postoperative abscess
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Pseudomembranous colitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Psittacosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Psoas abscess
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Pulmonary tuberculosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Renal abscess
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Sinusitis fungal
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Soft tissue infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Streptococcal sepsis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Subdiaphragmatic abscess
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Toxic shock syndrome
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Tracheobronchitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Urethritis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Urinary tract infection bacterial
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Viral infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Abdominal sepsis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Abscess
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Anal fistula infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Atypical pneumonia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Bacterial infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Bacteriuria
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Candiduria
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Device related infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Escherichia infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Escherichia urinary tract infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Fungaemia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Graft infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Haematoma infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Helicobacter infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Herpes simplex
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Herpes zoster disseminated
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Infected skin ulcer
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Klebsiella bacteraemia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Lymph node tuberculosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Medical device site infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Meningitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Meningitis pneumococcal
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Mycobacterial infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Neutropenic sepsis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Pneumonia influenzal
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Pneumonia viral
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Pseudomonas infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Rectal abscess
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Respiratory moniliasis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Testicular abscess
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Viral upper respiratory tract infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Vulvitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Wound infection staphylococcal
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Herpes zoster meningitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Ophthalmic herpes zoster
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Acetabulum fracture
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Anastomotic leak
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Ankle fracture
|
0.10%
6/5784 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/5734 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Burns second degree
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Carbon monoxide poisoning
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Cataract operation complication
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Chest injury
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Clavicle fracture
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Comminuted fracture
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Concussion
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Contusion
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6219 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Coronary artery reocclusion
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Craniocerebral injury
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Electrical burn
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Facial bones fracture
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Fall
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6071 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Femoral neck fracture
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.25%
4/1573 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Femur fracture
|
0.09%
5/5784 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6071 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.23%
14/6219 • Number of events 14 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
1/59 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Fibula fracture
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Foot fracture
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Forearm fracture
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Hand fracture
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Head injury
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Hip fracture
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.27%
4/1464 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Humerus fracture
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/5734 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Incarcerated incisional hernia
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Joint dislocation
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Joint injury
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Kidney contusion
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Laceration
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Ligament rupture
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Ligament sprain
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Limb injury
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Lower limb fracture
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Lumbar vertebral fracture
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Meniscus injury
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Multiple fractures
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Multiple injuries
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Patella fracture
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Pneumothorax traumatic
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Post procedural haemorrhage
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Postoperative wound complication
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Procedural pain
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Radius fracture
|
0.07%
4/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.09%
5/5734 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
8/6071 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6219 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Respiratory fume inhalation disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Rib fracture
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/5734 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6071 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Road traffic accident
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/5734 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Skin abrasion
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Skull fracture
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Snake bite
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Spinal compression fracture
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6071 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
1/59 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Spinal cord injury
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Spinal fracture
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Subdural haematoma
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.25%
4/1573 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Tendon rupture
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Tibia fracture
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Traumatic shock
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Ulna fracture
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Upper limb fracture
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Blood creatine phosphokinase increased
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Blood heavy metal increased
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Accident
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Back injury
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Bone fissure
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Burns third degree
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Cervical vertebral fracture
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Chemical poisoning
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Compression fracture
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Eye penetration
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Face injury
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Foreign body
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Fractured sacrum
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Gun shot wound
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Incisional hernia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Injury
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Muscle rupture
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Muscle strain
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Nerve root injury cervical
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Overdose
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Pelvic fracture
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Poisoning
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Post procedural complication
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Procedural intestinal perforation
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Pubis fracture
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Spinal cord injury cervical
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Splenic rupture
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Subdural haemorrhage
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Synovial rupture
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Tendon injury
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Thermal burn
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Thoracic vertebral fracture
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Toxicity to various agents
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6071 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Traumatic fracture
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Osteochondritis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Traumatic intracranial haemorrhage
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Vascular graft occlusion
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Vascular pseudoaneurysm ruptured
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Wound
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Wound dehiscence
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Wrist fracture
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Accidental overdose
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Aneurysm perforation
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Deep vein thrombosis postoperative
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Limb crushing injury
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Post procedural pulmonary embolism
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Seroma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Skin wound
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Sternal fracture
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Vascular pseudoaneurysm
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Wound evisceration
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Anticoagulation drug level above therapeutic
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Blood glucose fluctuation
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Blood pressure increased
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Haemoglobin decreased
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Heart rate decreased
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Liver function test abnormal
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Weight increased
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.12%
7/6071 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.41%
6/1464 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Diabetes mellitus
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Diabetic ketoacidosis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Hyperammonaemia
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Hyperlipidaemia
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Hypertriglyceridaemia
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Hypoglycaemia
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6071 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.20%
3/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Malnutrition
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Metabolic acidosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Type 1 diabetes mellitus
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Type 2 diabetes mellitus
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6071 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.11%
7/6219 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Cachexia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Diabetes mellitus inadequate control
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Electrolyte imbalance
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Failure to thrive
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Gout
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Hypovolaemia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Ketoacidosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Lactic acidosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Obesity
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Hypocalcaemia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Hypophagia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Marasmus
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Arthropathy
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Bursitis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Fasciitis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Intervertebral disc disorder
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Intervertebral disc protrusion
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.12%
7/5734 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Osteitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Osteoarthritis
|
0.12%
7/5784 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.09%
5/5734 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.23%
14/6071 • Number of events 14 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.23%
14/6219 • Number of events 14 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.64%
10/1573 • Number of events 10 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.48%
7/1464 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Osteoporosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Pathological fracture
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Periarthritis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Polymyalgia rheumatica
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Polymyositis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Rhabdomyolysis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Rheumatoid arthritis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Rotator cuff syndrome
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Sjogren's syndrome
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Soft tissue mass
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Spinal column stenosis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.25%
4/1573 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Spinal osteoarthritis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Spondyloarthropathy
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Spondylolisthesis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Still's disease adult onset
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Systemic lupus erythematosus
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Tenosynovitis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Acquired claw toe
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Arthritis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Arthrofibrosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Cervical spinal stenosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Costochondritis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Foot deformity
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Gouty arthritis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Joint destruction
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Joint effusion
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Meniscal degeneration
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Myositis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Osteochondrosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Osteolysis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Osteonecrosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Pseudarthrosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Spinal disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Spinal pain
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Synovial cyst
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Synovitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Tendonitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Trigger finger
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Chondrocalcinosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Chondropathy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Mixed connective tissue disease
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Osteoporotic fracture
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acral lentiginous melanoma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acute leukaemia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acute monocytic leukaemia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acute myeloid leukaemia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma of colon
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
1/59 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adult t-cell lymphoma/leukaemia
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B precursor type acute leukaemia
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell lymphoma
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Basal cell carcinoma
|
0.07%
4/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm of thyroid gland
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign ovarian tumour
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign renal neoplasm
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign soft tissue neoplasm
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bile duct adenocarcinoma
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bile duct cancer
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder cancer
|
0.07%
4/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/5734 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.21%
13/6219 • Number of events 13 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder cancer recurrent
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Brain injury
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder neoplasm
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bowen's disease
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Brain neoplasm benign
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer
|
0.12%
7/5784 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6219 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
1/59 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer in situ
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bronchial carcinoma
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cervix carcinoma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cervix carcinoma recurrent
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cholangiocarcinoma
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6219 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic lymphocytic leukaemia
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic myeloid leukaemia
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon adenoma
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon cancer
|
0.12%
7/5784 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.12%
7/5734 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6071 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.11%
7/6219 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon cancer metastatic
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Endometrial adenocarcinoma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Fallopian tube cancer
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gallbladder cancer
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastric cancer
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.12%
7/6071 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastrointestinal carcinoma
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Glioblastoma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Glioblastoma multiforme
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Glioma
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatic cancer
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatic neoplasm
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intestinal adenocarcinoma
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intraductal proliferative breast lesion
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Invasive ductal breast carcinoma
|
0.07%
4/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Laryngeal cancer
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Laryngeal neoplasm
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leukaemia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lip and/or oral cavity cancer
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung adenocarcinoma
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
8/6219 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung adenocarcinoma stage i
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung adenocarcinoma stage iii
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung cancer metastatic
|
0.07%
4/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6071 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung neoplasm
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung neoplasm malignant
|
0.17%
10/5784 • Number of events 10 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/5734 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.26%
16/6071 • Number of events 16 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.18%
11/6219 • Number of events 11 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.45%
7/1573 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.27%
4/1464 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphoma
|
0.02%
1/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant melanoma
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Meningioma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to central nervous system
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to liver
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to lymph nodes
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to peritoneum
|
0.07%
4/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastasis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic malignant melanoma
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic neoplasm
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic squamous cell carcinoma
|
0.02%
1/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasm malignant
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neuroendocrine carcinoma
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-hodgkin's lymphoma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal adenocarcinoma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal cancer metastatic
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal carcinoma
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal squamous cell carcinoma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian cancer
|
0.07%
4/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian neoplasm
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic carcinoma
|
0.07%
4/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.12%
7/5734 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6071 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
8/6219 • Number of events 9 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic carcinoma metastatic
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Restless legs syndrome
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Phaeochromocytoma
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Plasma cell myeloma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer
|
0.12%
7/5784 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.21%
12/5734 • Number of events 12 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.26%
16/6071 • Number of events 16 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.16%
10/6219 • Number of events 10 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.27%
4/1464 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer metastatic
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectal adenoma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cancer
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cell carcinoma
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal neoplasm
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal oncocytoma
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Salivary gland cancer
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small intestine adenocarcinoma
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of the oral cavity
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Sweat gland tumour
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid cancer
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Transitional cell carcinoma metastatic
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Uterine cancer
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Uterine leiomyoma
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vulval cancer
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acute promyelocytic leukaemia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma gastric
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma pancreas
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adrenal adenoma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adrenal gland cancer
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anaplastic thyroid cancer
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Angioimmunoblastic t-cell lymphoma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm of orbit
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder papilloma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder transitional cell carcinoma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder transitional cell carcinoma recurrent
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bone cancer
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Brain cancer metastatic
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Brain neoplasm
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Brain neoplasm malignant
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer metastatic
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bronchial neoplasm
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Carcinoid tumour of the small bowel
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Carcinoid tumour pulmonary
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon neoplasm
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Diffuse large b-cell lymphoma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Diffuse large b-cell lymphoma stage iv
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Follicular thyroid cancer
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastrointestinal neoplasm
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastrointestinal stromal tumour
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastrointestinal tract adenoma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Glomus tumour
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatic cancer metastatic
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatocellular carcinoma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hypergammaglobulinaemia benign monoclonal
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Invasive lobular breast carcinoma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Invasive papillary breast carcinoma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Large cell lung cancer
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Large intestine benign neoplasm
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lip squamous cell carcinoma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lipoma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung adenocarcinoma metastatic
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant fibrous histiocytoma of bone
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant lymphoma unclassifiable high grade
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant mast cell neoplasm
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant melanoma in situ
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of ampulla of vater
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant palate neoplasm
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant pleural effusion
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Melanocytic naevus
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Meningioma benign
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mesothelioma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to adrenals
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to bone
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to gastrointestinal tract
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to lung
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to pleura
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to stomach
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic carcinoma of the bladder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic gastric cancer
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic renal cell carcinoma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Myelodysplastic syndrome
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nasopharyngeal cancer
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-small cell lung cancer
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-small cell lung cancer stage iv
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal adenocarcinoma metastatic
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian cancer recurrent
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian epithelial cancer
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian fibroma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell teratoma benign
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic neoplasm
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic neuroendocrine tumour
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Papillary thyroid cancer
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Paraganglion neoplasm
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Parathyroid tumour benign
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pituitary tumour benign
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pleural mesothelioma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer recurrent
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostatic adenoma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectal adenocarcinoma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
1/59 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectal cancer
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectal cancer recurrent
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cancer metastatic
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cell carcinoma recurrent
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Sarcoma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Skin cancer
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small cell lung cancer
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Spinal claudication
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small cell lung cancer metastatic
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Spinal cord neoplasm
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of lung
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of skin
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
T-cell lymphoma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Throat cancer
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid neoplasm
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tongue neoplasm malignant stage unspecified
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Transitional cell carcinoma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour haemorrhage
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Urethral neoplasm
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Abdominal neoplasm
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anaplastic astrocytoma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm of bladder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cholesteatoma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hypopharyngeal cancer
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of unknown primary site
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasm prostate
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasm skin
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular neoplasm
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid adenoma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Central nervous system neoplasm
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Amnesia
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Amyotrophic lateral sclerosis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Balance disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Basal ganglia haemorrhage
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Basal ganglia infarction
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Basilar artery thrombosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Carotid artery disease
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Carotid artery stenosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Central nervous system lesion
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Cerebellar ischaemia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Cerebral haemorrhage
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6071 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
9/6219 • Number of events 9 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Cerebral infarction
|
0.14%
8/5784 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.23%
14/6071 • Number of events 14 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.26%
16/6219 • Number of events 17 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.34%
5/1464 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Cerebrovascular accident
|
0.12%
7/5784 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
11/5734 • Number of events 11 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.44%
27/6071 • Number of events 27 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.34%
21/6219 • Number of events 22 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.0%
16/1573 • Number of events 16 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.55%
8/1464 • Number of events 9 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
1/59 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Cervical myelopathy
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Demyelinating polyneuropathy
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Dizziness
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.20%
3/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Epilepsy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.20%
3/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Guillain-barre syndrome
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Haemorrhage intracranial
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Hemiplegia
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Hydrocephalus
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Hypoaesthesia
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Intracranial aneurysm
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Ischaemic stroke
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6071 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.20%
3/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Myelopathy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Nerve compression
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Neuritis cranial
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Paraesthesia
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Presyncope
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Radiculopathy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Status epilepticus
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Subarachnoid haemorrhage
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6219 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Syncope
|
0.07%
4/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/5734 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.15%
9/6071 • Number of events 9 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.21%
13/6219 • Number of events 14 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.61%
9/1464 • Number of events 10 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Thalamic infarction
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Transient global amnesia
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Transient ischaemic attack
|
0.07%
4/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.28%
17/6071 • Number of events 18 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
9/6219 • Number of events 9 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.38%
6/1573 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.48%
7/1464 • Number of events 9 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Trigeminal neuralgia
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Viiith nerve lesion
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Viith nerve paralysis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Aphasia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Brain stem syndrome
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Carotid artery thrombosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Carpal tunnel syndrome
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Cerebellar haemorrhage
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Cerebral artery embolism
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Cerebral artery thrombosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Cerebral ischaemia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.27%
4/1464 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Cerebrospinal fluid leakage
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Cerebrovascular disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Cerebrovascular insufficiency
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Cervicobrachial syndrome
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Dementia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Dementia alzheimer's type
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Drop attacks
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Dural arteriovenous fistula
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Dyspraxia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Generalised tonic-clonic seizure
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Haemorrhagic stroke
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Haemorrhagic transformation stroke
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Headache
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Hypertonia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Lacunar infarction
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Loss of consciousness
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Lumbar radiculopathy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Metabolic encephalopathy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Migraine
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Miller fisher syndrome
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Mixed dementia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Mononeuritis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Myasthenia gravis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Myoclonus
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Nervous system disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Neuralgia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Neuropathy peripheral
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Parkinsonism
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Partial seizures
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Polyneuropathy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Post herpetic neuralgia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Post polio syndrome
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Reversible ischaemic neurological deficit
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Ruptured cerebral aneurysm
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Sciatica
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.25%
4/1573 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Seizure
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Senile dementia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Somnolence
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Spondylitic myelopathy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Thalamus haemorrhage
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Thrombotic cerebral infarction
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Vasculitis cerebral
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Vertebrobasilar insufficiency
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Ataxia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Brain stem infarction
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Carotid artery occlusion
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Carotid sinus syndrome
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Cerebral atrophy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Cognitive disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
1/59 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Coma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Dementia with lewy bodies
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Diabetic coma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Diabetic neuropathy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Encephalopathy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Hemiparesis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Hypoxic-ischaemic encephalopathy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Intraventricular haemorrhage
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Memory impairment
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Paralysis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Parkinson's disease
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Progressive supranuclear palsy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Vascular dementia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Vascular encephalopathy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Postmenopausal haemorrhage
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Depressed mood
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Mental disorder due to a general medical condition
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Acute prerenal failure
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Bladder neck obstruction
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Cystitis haemorrhagic
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Dysuria
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Neurogenic bladder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Renal artery arteriosclerosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Urethral meatus stenosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Urinary tract disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Completed suicide
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Delirium
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Depression
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6071 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.20%
3/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Korsakoff's syndrome
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Major depression
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Psychotic disorder
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Schizoaffective disorder bipolar type
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Somatoform disorder
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Suicidal ideation
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Suicide attempt
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Abnormal behaviour
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Acute psychosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Adjustment disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Affective disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Alcohol withdrawal syndrome
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Anxiety disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Breathing-related sleep disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Confusional state
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Delirium febrile
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Disorientation
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Generalised anxiety disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Hallucination
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Mental disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Panic attack
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Panic disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Schizophrenia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Acute kidney injury
|
0.07%
4/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.23%
14/6071 • Number of events 14 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.18%
11/6219 • Number of events 11 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.38%
6/1573 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.68%
10/1464 • Number of events 11 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Bladder perforation
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Calculus bladder
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Calculus ureteric
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Chronic kidney disease
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.75%
11/1464 • Number of events 11 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Haematuria
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Nephrolithiasis
|
0.07%
4/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Renal colic
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Renal cyst
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Renal failure
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6071 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6219 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.38%
6/1573 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.34%
5/1464 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Renal hypertension
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Stress urinary incontinence
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Urethral haemorrhage
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Urethral polyp
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Urinary retention
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Azotaemia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Bladder prolapse
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Calculus urinary
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Cystitis interstitial
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Diabetic nephropathy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Glomerulonephritis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Hydronephrosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Nephroangiosclerosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Prerenal failure
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Renal artery occlusion
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Renal impairment
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Tubulointerstitial nephritis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Urethral stenosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Urinary incontinence
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Nephropathy toxic
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Benign prostatic hyperplasia
|
0.09%
5/5784 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Cystocele
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Fibrocystic breast disease
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Ovarian cyst
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Prostatomegaly
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Rectocele
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Uterine prolapse
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Uterovaginal prolapse
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Breast dysplasia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Endometrial hypertrophy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Prostatic obstruction
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Prostatitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Uterine enlargement
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Vaginal haemorrhage
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Vaginal prolapse
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Vaginal ulceration
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Atrophic vulvovaginitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary bulla
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Uterine polyp
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Acute respiratory failure
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.20%
3/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Asthma
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6219 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.20%
3/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Bronchospasm
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.16%
10/6071 • Number of events 11 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
8/6219 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.95%
15/1573 • Number of events 20 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.0%
15/1464 • Number of events 17 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Haemoptysis
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Lung disorder
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal polyps
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal septum deviation
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal turbinate hypertrophy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Pickwickian syndrome
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
8/6219 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonia aspiration
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.32%
5/1573 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.20%
3/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumothorax
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/5734 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.20%
12/6071 • Number of events 12 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.35%
22/6219 • Number of events 22 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.32%
5/1573 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.27%
4/1464 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary mass
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary oedema
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/5734 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.16%
10/6071 • Number of events 10 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
12/6219 • Number of events 12 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.64%
10/1573 • Number of events 10 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.34%
5/1464 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Acute pulmonary oedema
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.20%
3/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Aspiration
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Atelectasis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Bronchiectasis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Bronchitis chronic
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Diaphragmatic disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Emphysema
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.20%
3/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Haemothorax
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Idiopathic pulmonary fibrosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Interstitial lung disease
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Paranasal cyst
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural calcification
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Pleuritic pain
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary congestion
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary fibrosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory acidosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory arrest
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory distress
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Sleep apnoea syndrome
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Decubitus ulcer
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Dermal cyst
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Dermatitis allergic
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Dermatitis contact
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Diabetic foot
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Psoriasis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Skin ulcer
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Urticaria
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Hyperventilation
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary cavitation
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Dermatitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Dermatomyositis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Eczema
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Erythema multiforme
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Hyperkeratosis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Leukoplakia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Actinic keratosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Angioedema
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Drug eruption
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Lichen planus
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Skin necrosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Stasis dermatitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Cardiac pacemaker replacement
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Rectal polypectomy
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Hospitalisation
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Aneurysm ruptured
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Aortic aneurysm
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Aortic aneurysm rupture
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Aortic dissection
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Aortic rupture
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Aortic stenosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Arterial thrombosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Arteriosclerosis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6219 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Circulatory collapse
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Deep vein thrombosis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6219 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.32%
5/1573 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.27%
4/1464 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Haematoma
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.34%
5/1464 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Haemorrhage
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Hypertension
|
0.12%
7/5784 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.09%
5/5734 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.26%
16/6071 • Number of events 16 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.26%
16/6219 • Number of events 18 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.32%
5/1573 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.96%
14/1464 • Number of events 15 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Hypertensive crisis
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.11%
7/6219 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.25%
4/1573 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Hypovolaemic shock
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Internal haemorrhage
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Peripheral embolism
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Peripheral ischaemia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Polyarteritis nodosa
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Shock haemorrhagic
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Temporal arteritis
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Thrombophlebitis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Venous thrombosis limb
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Aneurysm
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Angiodysplasia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Aortic arteriosclerosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Aortic dilatation
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Bleeding varicose vein
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Embolism
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Essential hypertension
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Femoral artery occlusion
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Haemodynamic instability
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Hypertensive emergency
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Hypotension
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.25%
4/1573 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.27%
4/1464 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Inferior vena caval occlusion
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Intermittent claudication
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Microscopic polyangiitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Orthostatic hypotension
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.20%
3/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Peripheral arterial occlusive disease
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6071 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.20%
3/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
2.8%
2/72 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Peripheral artery stenosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Peripheral artery thrombosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Peripheral vascular disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Peripheral venous disease
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Superior vena cava syndrome
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Varicose ulceration
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Vasculitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Aortic occlusion
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Arterial disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Arteriovenous fistula
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Blood pressure inadequately controlled
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Diabetic vascular disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Femoral artery aneurysm
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Labile hypertension
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Orthostatic hypertension
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Peripheral artery aneurysm
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Thromboangiitis obliterans
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Thrombosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Vascular disorders
Varicose vein
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
Other adverse events
| Measure |
Non-Frail-HZ/su
n=5784 participants at risk
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were categorized as non-frail.
|
Non-Frail-Placebo
n=5734 participants at risk
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as non-frail.
|
Pre-Frail-HZ/su
n=6071 participants at risk
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were categorized as pre-frail.
|
Pre-Frail-Placebo
n=6219 participants at risk
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as pre-frail.
|
Frail-HZ/su
n=1573 participants at risk
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were categorized as frail.
|
Frail-Placebo
n=1464 participants at risk
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were categorized as frail.
|
Unknown-HZ/su
n=59 participants at risk
Adults aged ≥50 years of age who received HZ/su vaccine (in Zoster-006/022 study) and were not assigned a frailty category.
|
Unknown-Placebo
n=72 participants at risk
Adults aged ≥50 years of age who received placebo (in Zoster-006/022 study) and were not assigned a frailty category.
|
|---|---|---|---|---|---|---|---|---|
|
Blood and lymphatic system disorders
Anaemia
|
0.07%
4/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.27%
4/1464 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Blood and lymphatic system disorders
Haemorrhagic diathesis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Blood and lymphatic system disorders
Iron deficiency anaemia
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.27%
4/1464 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Blood and lymphatic system disorders
Leukopenia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Blood and lymphatic system disorders
Lymph node pain
|
0.10%
6/5784 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Blood and lymphatic system disorders
Lymphadenitis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Blood and lymphatic system disorders
Lymphadenopathy
|
0.16%
9/5784 • Number of events 10 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6071 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Blood and lymphatic system disorders
Macrocytosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Blood and lymphatic system disorders
Normochromic normocytic anaemia
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Blood and lymphatic system disorders
Thrombocytosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Angina pectoris
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Angina unstable
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Arrhythmia
|
0.03%
2/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6071 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
9/6219 • Number of events 9 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Arrhythmia supraventricular
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Atrial fibrillation
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Atrial flutter
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Atrioventricular block
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Bradycardia
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Cardiac discomfort
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Cardiac disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
1/59 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Cardiac failure
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.20%
3/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Cardiac failure acute
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Cardiac failure chronic
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Cardiac failure congestive
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Cardiac flutter
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Cardiac valve disease
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Cardiovascular disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Coronary artery disease
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Coronary artery occlusion
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Extrasystoles
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Hypertensive heart disease
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Mitral valve disease
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Mitral valve incompetence
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Mitral valve prolapse
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Myocardial ischaemia
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Myocarditis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Palpitations
|
0.10%
6/5784 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.09%
5/5734 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.18%
11/6071 • Number of events 11 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6219 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
1/59 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Sinus bradycardia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Sinus node dysfunction
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Supraventricular extrasystoles
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Supraventricular tachycardia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Tachyarrhythmia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Tachycardia
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Tachycardia paroxysmal
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Cardiac disorders
Ventricular extrasystoles
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Congenital, familial and genetic disorders
Malformation venous
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Ear and labyrinth disorders
Cerumen impaction
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Ear and labyrinth disorders
Deafness neurosensory
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Ear and labyrinth disorders
Ear discomfort
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Ear and labyrinth disorders
Ear disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Ear and labyrinth disorders
Ear pain
|
0.26%
15/5784 • Number of events 15 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.12%
7/5734 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6071 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6219 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.25%
4/1573 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Ear and labyrinth disorders
Eustachian tube disorder
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Ear and labyrinth disorders
Hypoacusis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Ear and labyrinth disorders
Meniere's disease
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Ear and labyrinth disorders
Middle ear effusion
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Ear and labyrinth disorders
Motion sickness
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Ear and labyrinth disorders
Otorrhoea
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Ear and labyrinth disorders
Sudden hearing loss
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Ear and labyrinth disorders
Tinnitus
|
0.07%
4/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/5734 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.12%
7/6071 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.11%
7/6219 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Ear and labyrinth disorders
Vertigo
|
0.24%
14/5784 • Number of events 15 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.12%
7/5734 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.36%
22/6071 • Number of events 22 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.34%
21/6219 • Number of events 23 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.38%
6/1573 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.55%
8/1464 • Number of events 9 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Ear and labyrinth disorders
Vertigo positional
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Endocrine disorders
Androgen deficiency
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Endocrine disorders
Autoimmune thyroiditis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Endocrine disorders
Basedow's disease
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Endocrine disorders
Goitre
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Endocrine disorders
Hyperparathyroidism
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Endocrine disorders
Hyperthyroidism
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Endocrine disorders
Hypogonadism
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Endocrine disorders
Hypothyroidism
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Abnormal sensation in eye
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Asthenopia
|
0.07%
4/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Blepharitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Blepharospasm
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Cataract
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/5734 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6071 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.21%
13/6219 • Number of events 13 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.38%
6/1573 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.34%
5/1464 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Chalazion
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Chorioretinal atrophy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Chorioretinopathy
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Chromatopsia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Conjunctival degeneration
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Conjunctival haemorrhage
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/5734 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6219 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Conjunctival hyperaemia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Conjunctivitis allergic
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Corneal erosion
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Dark circles under eyes
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Diabetic retinopathy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Diplopia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Dry eye
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/5734 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
8/6219 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Eczema eyelids
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Enophthalmos
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Erythema of eyelid
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Eye allergy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Eye discharge
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Eye disorder
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Eye haemorrhage
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Eye inflammation
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Eye irritation
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Eye pain
|
0.07%
4/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/5734 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
8/6071 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Eye pruritus
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Eye swelling
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Eyelid function disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Eyelid oedema
|
0.02%
1/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Eyelid ptosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Eyelid rash
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Eyelids pruritus
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Foreign body sensation in eyes
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Glaucoma
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Keratitis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Lacrimation decreased
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Lacrimation increased
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Macular degeneration
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Macular fibrosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Maculopathy
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Narrow anterior chamber angle
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Neovascular age-related macular degeneration
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Ocular discomfort
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Ocular hyperaemia
|
0.07%
4/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Ocular hypertension
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Ophthalmic vein thrombosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Optic ischaemic neuropathy
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Panophthalmitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Periorbital oedema
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Photopsia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Posterior capsule opacification
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Retinal degeneration
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Retinal detachment
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Retinopathy hypertensive
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Trichiasis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Ulcerative keratitis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Uveitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Vision blurred
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Visual acuity reduced
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Visual impairment
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Vitreous detachment
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Eye disorders
Vitreous floaters
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/5734 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Abdominal discomfort
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/5734 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6071 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
8/6219 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Abdominal distension
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.12%
7/6071 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Abdominal pain
|
0.29%
17/5784 • Number of events 18 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.21%
12/5734 • Number of events 14 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.25%
15/6071 • Number of events 15 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.21%
13/6219 • Number of events 13 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.25%
4/1573 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.41%
6/1464 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Abdominal pain lower
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.40%
23/5784 • Number of events 25 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.49%
28/5734 • Number of events 30 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.38%
23/6071 • Number of events 24 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.51%
32/6219 • Number of events 34 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.38%
6/1573 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.34%
5/1464 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
1/59 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Abnormal faeces
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Acid peptic disease
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Aerophagia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Anal fissure
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Anal haemorrhage
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Anal inflammation
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Anal pruritus
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Aphthous stomatitis
|
0.07%
4/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Aptyalism
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Change of bowel habit
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Chapped lips
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Cheilitis
|
0.05%
3/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Chronic gastritis
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Coeliac disease
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Colitis
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Colitis ulcerative
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Constipation
|
0.17%
10/5784 • Number of events 10 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.21%
12/5734 • Number of events 13 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.30%
18/6071 • Number of events 18 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.21%
13/6219 • Number of events 14 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.38%
6/1573 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.48%
7/1464 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
1/59 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Crohn's disease
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Dental caries
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Dental necrosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Diarrhoea
|
0.97%
56/5784 • Number of events 59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.72%
41/5734 • Number of events 43 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.82%
50/6071 • Number of events 52 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.85%
53/6219 • Number of events 55 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.1%
18/1573 • Number of events 18 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.89%
13/1464 • Number of events 14 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
1/59 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Diverticulum
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Diverticulum intestinal
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Dry mouth
|
0.10%
6/5784 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
8/6071 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.16%
10/6219 • Number of events 10 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Duodenal ulcer
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Dyspepsia
|
0.24%
14/5784 • Number of events 15 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
11/5734 • Number of events 11 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.25%
15/6071 • Number of events 18 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.26%
16/6219 • Number of events 18 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.27%
4/1464 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Dysphagia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Enteritis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Epigastric discomfort
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Eructation
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Faeces discoloured
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Flatulence
|
0.02%
1/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Food poisoning
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Functional gastrointestinal disorder
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Gastric disorder
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Gastric ulcer
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Gastritis
|
0.16%
9/5784 • Number of events 11 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/5734 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.25%
15/6071 • Number of events 17 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.18%
11/6219 • Number of events 11 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Gastritis erosive
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Gastroduodenitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Gastrointestinal disorder
|
0.09%
5/5784 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Gastrointestinal haemorrhage
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Gastrointestinal pain
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Gastrointestinal sounds abnormal
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Gastrooesophageal reflux disease
|
0.12%
7/5784 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
8/5734 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.16%
10/6071 • Number of events 10 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
9/6219 • Number of events 9 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.20%
3/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
1/59 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Gastrooesophageal sphincter insufficiency
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Gingival bleeding
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Gingival pain
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Gingival swelling
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Glossitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Glossodynia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Haematochezia
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Haemorrhoidal haemorrhage
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Haemorrhoids
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.16%
9/5734 • Number of events 9 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.18%
11/6071 • Number of events 11 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Hiatus hernia
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Hyperchlorhydria
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Hypoaesthesia oral
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Ileus
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Infrequent bowel movements
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Inguinal hernia
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Intestinal cyst
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Intestinal polyp
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Irritable bowel syndrome
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Large intestine polyp
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Asthenia
|
0.66%
38/5784 • Number of events 41 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/5734 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.43%
26/6071 • Number of events 28 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.21%
13/6219 • Number of events 13 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.51%
8/1573 • Number of events 9 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.20%
3/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
2.8%
2/72 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Lip blister
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Lip disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Lip dry
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Lip pain
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Lip swelling
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Lip ulceration
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Loose tooth
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Melanosis coli
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Mouth haemorrhage
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Mouth swelling
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Mouth ulceration
|
0.12%
7/5784 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.09%
5/5734 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.12%
7/6071 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.27%
4/1464 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
1/59 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Nausea
|
1.6%
92/5784 • Number of events 104 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.49%
28/5734 • Number of events 36 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.2%
71/6071 • Number of events 80 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.51%
32/6219 • Number of events 34 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.1%
18/1573 • Number of events 21 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.55%
8/1464 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Noninfective gingivitis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Odynophagia
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Oesophageal discomfort
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Oesophagitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Oral disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Oral mucosal blistering
|
0.09%
5/5784 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Oral pain
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Pancreatic steatosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Paraesthesia oral
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Peptic ulcer
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Periodontal disease
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Rectal haemorrhage
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Rectal polyp
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Rectal prolapse
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Retching
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Salivary gland calculus
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Salivary gland cyst
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Salivary hypersecretion
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Sensitivity of teeth
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Stomatitis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.09%
5/5734 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Swollen tongue
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Tongue blistering
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Tongue coated
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Tongue disorder
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Tongue pruritus
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Tongue ulceration
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Tooth deposit
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Tooth disorder
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Tooth erosion
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Tooth impacted
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Toothache
|
0.38%
22/5784 • Number of events 23 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.44%
25/5734 • Number of events 25 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.21%
13/6071 • Number of events 13 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.34%
21/6219 • Number of events 22 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.25%
4/1573 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Umbilical hernia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Gastrointestinal disorders
Vomiting
|
0.45%
26/5784 • Number of events 27 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.17%
10/5734 • Number of events 10 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.30%
18/6071 • Number of events 18 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.27%
17/6219 • Number of events 20 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.57%
9/1573 • Number of events 9 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.48%
7/1464 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Administration site pain
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Administration site reaction
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Adverse drug reaction
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Axillary pain
|
0.10%
6/5784 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Chest discomfort
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6071 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Chest pain
|
0.17%
10/5784 • Number of events 11 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.17%
10/5734 • Number of events 12 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.31%
19/6071 • Number of events 20 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
9/6219 • Number of events 10 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.34%
5/1464 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Chills
|
4.4%
252/5784 • Number of events 297 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.28%
16/5734 • Number of events 17 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
3.1%
189/6071 • Number of events 218 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.23%
14/6219 • Number of events 15 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
2.3%
36/1573 • Number of events 41 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
5.1%
3/59 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Cyst
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Device breakage
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Discomfort
|
0.05%
3/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Face oedema
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Facial pain
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6071 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Fatigue
|
4.4%
252/5784 • Number of events 300 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.82%
47/5734 • Number of events 49 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
3.0%
182/6071 • Number of events 216 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.2%
75/6219 • Number of events 78 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
2.2%
34/1573 • Number of events 44 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.55%
8/1464 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
3.4%
2/59 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Feeling abnormal
|
0.09%
5/5784 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Feeling cold
|
0.48%
28/5784 • Number of events 30 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/5734 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.33%
20/6071 • Number of events 22 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Feeling hot
|
0.47%
27/5784 • Number of events 30 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.26%
16/6071 • Number of events 16 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.11%
7/6219 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Feeling jittery
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Feeling of body temperature change
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Gait disturbance
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
General physical health deterioration
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Ill-defined disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Implant site hypersensitivity
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Induration
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Inflammation
|
0.07%
4/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Influenza like illness
|
1.1%
61/5784 • Number of events 78 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.37%
21/5734 • Number of events 21 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.64%
39/6071 • Number of events 43 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.29%
18/6219 • Number of events 20 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.51%
8/1573 • Number of events 10 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.20%
3/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Injection site atrophy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Injection site bruising
|
0.28%
16/5784 • Number of events 19 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.28%
16/5734 • Number of events 17 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.26%
16/6071 • Number of events 16 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.21%
13/6219 • Number of events 15 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.20%
3/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
1/59 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Injection site coldness
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Injection site discolouration
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Injection site discomfort
|
0.17%
10/5784 • Number of events 10 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.15%
9/6071 • Number of events 9 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Injection site eczema
|
0.05%
3/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Injection site erythema
|
10.5%
607/5784 • Number of events 819 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.24%
14/5734 • Number of events 14 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
8.8%
535/6071 • Number of events 700 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.35%
22/6219 • Number of events 24 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
7.3%
115/1573 • Number of events 139 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
6.8%
4/59 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Injection site haematoma
|
0.16%
9/5784 • Number of events 9 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.09%
5/5734 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Injection site haemorrhage
|
0.09%
5/5784 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/5734 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6071 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Injection site hyperaesthesia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Injection site hypersensitivity
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Injection site hypoaesthesia
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Injection site induration
|
0.36%
21/5784 • Number of events 23 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.41%
25/6071 • Number of events 29 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.45%
7/1573 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Injection site inflammation
|
0.33%
19/5784 • Number of events 21 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.35%
21/6071 • Number of events 22 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.57%
9/1573 • Number of events 9 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Injection site injury
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Injection site irritation
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Injection site joint pain
|
0.36%
21/5784 • Number of events 25 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.36%
22/6071 • Number of events 22 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Injection site lymphadenopathy
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Injection site macule
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Injection site mass
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6071 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Injection site movement impairment
|
0.07%
4/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Injection site nodule
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Injection site oedema
|
0.21%
12/5784 • Number of events 14 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.33%
20/6071 • Number of events 21 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.45%
7/1573 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Injection site pain
|
25.1%
1454/5784 • Number of events 2157 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.6%
94/5734 • Number of events 110 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
22.0%
1334/6071 • Number of events 1877 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.8%
109/6219 • Number of events 119 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
18.9%
298/1573 • Number of events 404 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
2.0%
29/1464 • Number of events 34 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
13.6%
8/59 • Number of events 12 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
4.2%
3/72 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Injection site papule
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Injection site paraesthesia
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Injection site pruritus
|
2.5%
144/5784 • Number of events 170 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
11/5734 • Number of events 13 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.9%
115/6071 • Number of events 140 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.26%
16/6219 • Number of events 17 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
2.3%
36/1573 • Number of events 39 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.20%
3/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Injection site rash
|
0.52%
30/5784 • Number of events 32 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.36%
22/6071 • Number of events 24 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Injection site reaction
|
0.47%
27/5784 • Number of events 31 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/5734 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.44%
27/6071 • Number of events 31 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.11%
7/6219 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.25%
4/1573 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
1/59 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Injection site swelling
|
7.9%
455/5784 • Number of events 587 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
8/5734 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
6.4%
390/6071 • Number of events 490 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
8/6219 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
5.6%
88/1573 • Number of events 112 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.27%
4/1464 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
3.4%
2/59 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Injection site ulcer
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Injection site urticaria
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6071 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Injection site vesicles
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Injection site warmth
|
1.1%
63/5784 • Number of events 68 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.1%
66/6071 • Number of events 75 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.76%
12/1573 • Number of events 14 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
1/59 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Injury associated with device
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Local swelling
|
0.09%
5/5784 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.12%
7/5734 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Malaise
|
2.0%
113/5784 • Number of events 126 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.33%
19/5734 • Number of events 20 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
87/6071 • Number of events 99 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.26%
16/6219 • Number of events 16 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.3%
20/1573 • Number of events 21 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.20%
3/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
1/59 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Metaplasia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Mucous membrane disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Nodule
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Oedema
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Oedema peripheral
|
0.09%
5/5784 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6071 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6219 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.48%
7/1464 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
1/59 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Pain
|
1.7%
98/5784 • Number of events 114 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.17%
10/5734 • Number of events 10 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.2%
71/6071 • Number of events 76 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.27%
17/6219 • Number of events 18 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.1%
17/1573 • Number of events 19 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.27%
4/1464 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
1/59 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Peripheral swelling
|
0.07%
4/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6071 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.25%
4/1573 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Polyp
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Pyrexia
|
9.7%
560/5784 • Number of events 678 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.58%
33/5734 • Number of events 35 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
5.6%
341/6071 • Number of events 410 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.47%
29/6219 • Number of events 30 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
3.7%
58/1573 • Number of events 67 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.34%
5/1464 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
3.4%
2/59 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Reactogenicity event
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Sluggishness
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Swelling
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Temperature intolerance
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Tenderness
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Thirst
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Ulcer haemorrhage
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Vaccination site coldness
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Vaccination site discolouration
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Vaccination site erythema
|
0.21%
12/5784 • Number of events 16 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.31%
19/6071 • Number of events 23 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.45%
7/1573 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Vaccination site haematoma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Vaccination site inflammation
|
0.02%
1/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Vaccination site irritation
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Vaccination site pain
|
0.52%
30/5784 • Number of events 37 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.41%
25/6071 • Number of events 29 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.32%
5/1573 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
1/59 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Vaccination site pruritus
|
0.03%
2/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Vaccination site reaction
|
0.09%
5/5784 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
8/6071 • Number of events 11 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Vaccination site swelling
|
0.14%
8/5784 • Number of events 11 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.15%
9/6071 • Number of events 9 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.25%
4/1573 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Vaccination site warmth
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Vessel puncture site erythema
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
General disorders
Vessel puncture site pain
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Hepatobiliary disorders
Biliary colic
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Hepatobiliary disorders
Cholecystitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Hepatobiliary disorders
Cholelithiasis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Hepatobiliary disorders
Chronic hepatitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Hepatobiliary disorders
Gallbladder polyp
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Hepatobiliary disorders
Hepatic cirrhosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Hepatobiliary disorders
Hepatic cyst
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Hepatobiliary disorders
Hepatic function abnormal
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Hepatobiliary disorders
Hepatic steatosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Hepatobiliary disorders
Hyperbilirubinaemia
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Hepatobiliary disorders
Hypertransaminasaemia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Hepatobiliary disorders
Liver disorder
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Immune system disorders
Allergy to arthropod sting
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Immune system disorders
Allergy to chemicals
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Immune system disorders
Allergy to plants
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Immune system disorders
Anaphylactic reaction
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Immune system disorders
Drug hypersensitivity
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Immune system disorders
Food allergy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Immune system disorders
Hypersensitivity
|
0.10%
6/5784 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.16%
9/5734 • Number of events 9 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.12%
7/6071 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.11%
7/6219 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Immune system disorders
Milk allergy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Immune system disorders
Multiple allergies
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Immune system disorders
Seasonal allergy
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Abdominal infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Abdominal wall abscess
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Abscess
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Abscess limb
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Abscess oral
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Acarodermatitis
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Acute sinusitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Acute tonsillitis
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Alveolar osteitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Anorectal cellulitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Arthritis bacterial
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Arthritis infective
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Bacterial infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Bacteriuria
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Blastocystis infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Body tinea
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Borrelia infection
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Breast abscess
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Bronchiolitis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Bronchitis
|
0.41%
24/5784 • Number of events 24 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.56%
32/5734 • Number of events 32 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.99%
60/6071 • Number of events 63 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.66%
41/6219 • Number of events 41 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.0%
16/1573 • Number of events 17 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.0%
15/1464 • Number of events 15 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Bronchitis viral
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Bronchopneumonia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Candida infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Carbuncle
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Cellulitis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6071 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.16%
10/6219 • Number of events 10 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.34%
5/1464 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Cellulitis orbital
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Cervicitis
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Chronic hepatitis b
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Chronic sinusitis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Conjunctivitis
|
0.12%
7/5784 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/5734 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.18%
11/6071 • Number of events 11 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.31%
19/6219 • Number of events 20 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.70%
11/1573 • Number of events 11 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.55%
8/1464 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Conjunctivitis bacterial
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Conjunctivitis viral
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Cystitis
|
0.24%
14/5784 • Number of events 14 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.17%
10/5734 • Number of events 11 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.28%
17/6071 • Number of events 18 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.24%
15/6219 • Number of events 16 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.32%
5/1573 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.27%
4/1464 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Dacryocystitis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Dengue fever
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Dermatophytosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Diarrhoea infectious
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Diverticulitis
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Ear infection
|
0.10%
6/5784 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.12%
7/5734 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6071 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.20%
3/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Eczema infected
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Enteritis infectious
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Epididymitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Erysipelas
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Erythema migrans
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Eye infection
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Eyelid infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Folliculitis
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Fungal infection
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Fungal skin infection
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Furuncle
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/5734 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Gastric infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Gastroenteritis
|
0.31%
18/5784 • Number of events 19 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.35%
20/5734 • Number of events 20 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.31%
19/6071 • Number of events 19 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.24%
15/6219 • Number of events 15 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.48%
7/1464 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Gastroenteritis viral
|
0.12%
7/5784 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.09%
5/5734 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.15%
9/6071 • Number of events 9 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Gastrointestinal fungal infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Gastrointestinal infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Genital candidiasis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Genital herpes
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Genital infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Gingivitis
|
0.09%
5/5784 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.12%
7/5734 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Groin abscess
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
H1n1 influenza
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Haemorrhoid infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Hand-foot-and-mouth disease
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Helicobacter infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Hepatic infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Herpes simplex
|
0.26%
15/5784 • Number of events 18 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.35%
20/5734 • Number of events 21 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.15%
9/6071 • Number of events 10 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.11%
7/6219 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.45%
7/1573 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.27%
4/1464 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Herpes virus infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Hordeolum
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Impetigo
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Infected bites
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Infected cyst
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Infected varicose vein
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Influenza
|
0.52%
30/5784 • Number of events 31 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.51%
29/5734 • Number of events 29 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.35%
21/6071 • Number of events 23 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.43%
27/6219 • Number of events 27 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.55%
8/1464 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Injection site cellulitis
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Injection site infection
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Kidney infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Labyrinthitis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Laryngitis
|
0.10%
6/5784 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Lobar pneumonia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Localised infection
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Lower respiratory tract infection
|
0.10%
6/5784 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/5734 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.18%
11/6071 • Number of events 11 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.23%
14/6219 • Number of events 15 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.95%
15/1573 • Number of events 15 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.41%
6/1464 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Lung infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Lyme disease
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Mastitis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Nail bed infection
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Nasopharyngitis
|
3.6%
211/5784 • Number of events 238 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
4.4%
251/5734 • Number of events 269 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
3.2%
193/6071 • Number of events 209 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
3.3%
208/6219 • Number of events 227 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
2.5%
40/1573 • Number of events 43 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
2.5%
36/1464 • Number of events 37 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
1/59 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Neuroborreliosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Omphalitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Onychomycosis
|
0.10%
6/5784 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.09%
5/5734 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.12%
7/6071 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.16%
10/6219 • Number of events 10 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.20%
3/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Ophthalmic herpes simplex
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Oral candidiasis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.27%
4/1464 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Oral fungal infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Oral herpes
|
0.61%
35/5784 • Number of events 37 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.38%
22/5734 • Number of events 23 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.41%
25/6071 • Number of events 29 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.29%
18/6219 • Number of events 18 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Oral infection
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Orchitis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Oropharyngeal candidiasis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Osteomyelitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Otitis externa
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.16%
10/6219 • Number of events 11 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Otitis externa fungal
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Otitis media
|
0.09%
5/5784 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.09%
5/5734 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Otitis media acute
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Otitis media chronic
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Parasitic gastroenteritis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Paronychia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Parotitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Perichondritis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Periodontitis
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Peritonsillar abscess
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Pharyngitis
|
0.38%
22/5784 • Number of events 22 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.31%
18/5734 • Number of events 18 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.49%
30/6071 • Number of events 30 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.50%
31/6219 • Number of events 34 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.32%
5/1573 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
1/59 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Pharyngitis bacterial
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Pharyngitis streptococcal
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Pharyngotonsillitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Pneumonia
|
0.09%
5/5784 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/5734 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.15%
9/6071 • Number of events 10 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.16%
10/6219 • Number of events 10 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.20%
3/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Post procedural infection
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Postoperative wound infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Pulpitis dental
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Pyelonephritis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Pyuria
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Rash pustular
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Respiratory tract infection
|
0.29%
17/5784 • Number of events 17 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.12%
7/5734 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.28%
17/6071 • Number of events 17 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
9/6219 • Number of events 9 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Respiratory tract infection viral
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Retinitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Rhinitis
|
0.29%
17/5784 • Number of events 20 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.38%
22/5734 • Number of events 24 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.31%
19/6071 • Number of events 19 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.29%
18/6219 • Number of events 19 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.38%
6/1573 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.27%
4/1464 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Rhinolaryngitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Rhinovirus infection
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Scrotal abscess
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Sinobronchitis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Sinusitis
|
0.41%
24/5784 • Number of events 25 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.45%
26/5734 • Number of events 26 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.49%
30/6071 • Number of events 31 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.35%
22/6219 • Number of events 23 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.32%
5/1573 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.61%
9/1464 • Number of events 9 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Skin bacterial infection
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Skin candida
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Skin infection
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Staphylococcal infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Subcutaneous abscess
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Tinea capitis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Tinea cruris
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Tinea infection
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Tinea manuum
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Tinea pedis
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Tinea versicolour
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Tonsillitis
|
0.09%
5/5784 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/5734 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Tonsillitis bacterial
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Tooth abscess
|
0.12%
7/5784 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
8/5734 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6071 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6219 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Tooth infection
|
0.10%
6/5784 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.20%
3/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Toxoplasmosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Tracheitis
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Tracheobronchitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Upper respiratory tract infection
|
1.7%
100/5784 • Number of events 107 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.3%
75/5734 • Number of events 79 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.5%
89/6071 • Number of events 96 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.2%
77/6219 • Number of events 85 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.5%
24/1573 • Number of events 24 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.96%
14/1464 • Number of events 15 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Urethritis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Urinary tract infection
|
0.47%
27/5784 • Number of events 27 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.63%
36/5734 • Number of events 37 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.64%
39/6071 • Number of events 41 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.64%
40/6219 • Number of events 41 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.1%
18/1573 • Number of events 18 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.75%
11/1464 • Number of events 12 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
1/59 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Vaginal infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6219 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Varicella
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Viral infection
|
0.10%
6/5784 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
8/5734 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.16%
10/6071 • Number of events 10 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6219 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.32%
5/1573 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Viral rash
|
0.02%
1/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Viral sinusitis
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Viral upper respiratory tract infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
1/59 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Vulvovaginal mycotic infection
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Infections and infestations
Wound infection
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Animal bite
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Ankle fracture
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Aqueous humour leakage
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Arthropod bite
|
0.14%
8/5784 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/5734 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.23%
14/6071 • Number of events 14 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
8/6219 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Arthropod sting
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Back injury
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Bite
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Bone contusion
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Burns first degree
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Burns second degree
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Cartilage injury
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Chest injury
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Hyperphagia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Clavicle fracture
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Compression fracture
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Concussion
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Contrast media reaction
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Contusion
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
8/5734 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.21%
13/6071 • Number of events 13 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
12/6219 • Number of events 13 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.51%
8/1573 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.27%
4/1464 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Corneal abrasion
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Craniocerebral injury
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Crush injury
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Epicondylitis
|
0.05%
3/5784 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Excoriation
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Eye injury
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Face injury
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Facial bones fracture
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Fall
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
8/5734 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.15%
9/6071 • Number of events 9 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.32%
5/1573 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.27%
4/1464 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Fibula fracture
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Foot fracture
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Forearm fracture
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Foreign body
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Foreign body in eye
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Hand fracture
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Head injury
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Heat stroke
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Hip fracture
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Humerus fracture
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Injury
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Injury corneal
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Joint dislocation
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Joint injury
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.09%
5/5734 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Laceration
|
0.07%
4/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6071 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Ligament injury
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Ligament rupture
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Ligament sprain
|
0.14%
8/5784 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.21%
12/5734 • Number of events 12 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.12%
7/6071 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
9/6219 • Number of events 9 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Limb injury
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
8/5734 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.12%
7/6071 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6219 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Lip injury
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Lower limb fracture
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Lumbar vertebral fracture
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Meniscus injury
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Mouth injury
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Multiple injuries
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Muscle injury
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Muscle rupture
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Muscle strain
|
0.10%
6/5784 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
8/6071 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Open fracture
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Patella fracture
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Post procedural haematuria
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Post procedural haemorrhage
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Post procedural inflammation
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Procedural pain
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.09%
5/5734 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6071 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Radius fracture
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Rib fracture
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/5734 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Road traffic accident
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Scratch
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Skeletal injury
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Skin abrasion
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/5734 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Skin injury
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Skin wound
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Soft tissue injury
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Spinal column injury
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Spinal compression fracture
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Spinal cord injury
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Spinal fracture
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Sunburn
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Tendon rupture
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Thermal burn
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Thoracic vertebral fracture
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Tibia fracture
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Tooth fracture
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Traumatic arthropathy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Traumatic haematoma
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Upper limb fracture
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Vaccination complication
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Wound
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6219 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Injury, poisoning and procedural complications
Wrist fracture
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.09%
5/5734 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Blood alkaline phosphatase increased
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Blood cholesterol increased
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Blood glucose increased
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Blood iron decreased
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Blood potassium decreased
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Blood potassium increased
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Blood pressure abnormal
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Blood pressure decreased
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Blood pressure diastolic increased
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Blood pressure increased
|
0.12%
7/5784 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.12%
7/6071 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Blood sodium decreased
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Blood testosterone decreased
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Blood thyroid stimulating hormone increased
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Blood uric acid increased
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Body temperature decreased
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Body temperature fluctuation
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Body temperature increased
|
0.93%
54/5784 • Number of events 57 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.76%
46/6071 • Number of events 53 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.45%
7/1573 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Cardiac murmur
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Catheterisation cardiac
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Electrocardiogram abnormal
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Gamma-glutamyltransferase increased
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Grip strength decreased
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Haemoglobin decreased
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Heart rate increased
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Heart rate irregular
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Helicobacter test positive
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Liver function test abnormal
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Precancerous cells present
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Protein urine present
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Serum ferritin decreased
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Transaminases increased
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Urine analysis abnormal
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Weight decreased
|
0.03%
2/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Investigations
Weight increased
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Abnormal loss of weight
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Cachexia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.17%
10/5784 • Number of events 10 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.26%
16/6071 • Number of events 16 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.32%
5/1573 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Diabetes mellitus
|
0.10%
6/5784 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/5734 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6071 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6219 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Diabetes mellitus inadequate control
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Dyslipidaemia
|
0.12%
7/5784 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.18%
11/6071 • Number of events 11 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Feeding disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Folate deficiency
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Glucose tolerance impaired
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Gout
|
0.09%
5/5784 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.21%
13/6071 • Number of events 15 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.45%
7/1573 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Hypercalcaemia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Hypercholesterolaemia
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.12%
7/5734 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.16%
10/6071 • Number of events 10 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Hyperlipidaemia
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6071 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.11%
7/6219 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Hypertriglyceridaemia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Hyperuricaemia
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Hypoglycaemia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.20%
3/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Hypovitaminosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Iron deficiency
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Lactose intolerance
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Obesity
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Polydipsia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Type 2 diabetes mellitus
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/5734 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
8/6071 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Vitamin b12 deficiency
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Metabolism and nutrition disorders
Vitamin d deficiency
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
1.9%
110/5784 • Number of events 120 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.2%
68/5734 • Number of events 73 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.6%
99/6071 • Number of events 107 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.2%
73/6219 • Number of events 86 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
22/1573 • Number of events 22 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.2%
18/1464 • Number of events 20 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
1/59 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Arthritis
|
0.09%
5/5784 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/5734 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6219 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Arthropathy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6219 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Axillary mass
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
1.5%
89/5784 • Number of events 95 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.1%
63/5734 • Number of events 69 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.3%
76/6071 • Number of events 85 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.3%
82/6219 • Number of events 90 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
26/1573 • Number of events 27 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.8%
27/1464 • Number of events 32 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Bone disorder
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Bone pain
|
0.09%
5/5784 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.12%
7/6071 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Bone swelling
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Bursitis
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.11%
7/6219 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Cervical spinal stenosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Chondrocalcinosis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Chondropathy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Coccydynia
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Costochondritis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Dupuytren's contracture
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Exostosis
|
0.07%
4/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Fibromyalgia
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Flank pain
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Foot deformity
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Gouty arthritis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Groin pain
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Iliolumbar syndrome
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Intervertebral disc degeneration
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Intervertebral disc protrusion
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Lacunar infarction
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Jaw cyst
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Joint stiffness
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Joint swelling
|
0.09%
5/5784 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.12%
7/5734 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Ligament disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Limb discomfort
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Lumbar spinal stenosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Metatarsalgia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Mobility decreased
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Monarthritis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Muscle contracture
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Muscle disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Muscle fatigue
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Muscle rigidity
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
0.17%
10/5784 • Number of events 10 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
8/5734 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.33%
20/6071 • Number of events 22 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
12/6219 • Number of events 13 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.38%
6/1573 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.20%
3/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Muscle tightness
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Muscle twitching
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.09%
5/5784 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/5734 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6071 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal discomfort
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
0.69%
40/5784 • Number of events 43 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.42%
24/5734 • Number of events 26 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.72%
44/6071 • Number of events 45 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.45%
28/6219 • Number of events 28 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.61%
9/1464 • Number of events 9 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal stiffness
|
0.22%
13/5784 • Number of events 14 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.12%
7/5734 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6071 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.11%
7/6219 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
4.2%
243/5784 • Number of events 297 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.63%
36/5734 • Number of events 43 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
2.9%
177/6071 • Number of events 202 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.82%
51/6219 • Number of events 56 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
2.0%
32/1573 • Number of events 39 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.61%
9/1464 • Number of events 11 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
3.4%
2/59 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Myofascial pain syndrome
|
0.03%
2/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.55%
32/5784 • Number of events 36 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.24%
14/5734 • Number of events 15 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.40%
24/6071 • Number of events 29 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.37%
23/6219 • Number of events 25 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.25%
4/1573 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.34%
5/1464 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Osteitis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Osteoarthritis
|
0.14%
8/5784 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.33%
19/5734 • Number of events 19 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.69%
42/6071 • Number of events 44 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.71%
44/6219 • Number of events 44 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.76%
12/1573 • Number of events 13 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.41%
6/1464 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
2.8%
2/72 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Osteochondrosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Osteopenia
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6219 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Osteoporosis
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
1/59 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.90%
52/5784 • Number of events 55 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.77%
44/5734 • Number of events 48 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.1%
67/6071 • Number of events 80 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.64%
40/6219 • Number of events 43 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
27/1573 • Number of events 29 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.96%
14/1464 • Number of events 16 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Pain in jaw
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Periarthritis
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Plantar fasciitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Polyarthritis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Polymyalgia rheumatica
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Rheumatic disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Rheumatoid arthritis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Rotator cuff syndrome
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Scoliosis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Soft tissue disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Soft tissue mass
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Spinal column stenosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Spinal disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Spinal osteoarthritis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Spinal pain
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Spondyloarthropathy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Spondylolisthesis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Spondylolysis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Synovial cyst
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Synovitis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Tendon disorder
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Tendon pain
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Tendonitis
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/5734 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.11%
7/6219 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Tenosynovitis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Tenosynovitis stenosans
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Torticollis
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Trigger finger
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Musculoskeletal and connective tissue disorders
Vertebral foraminal stenosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acrochordon
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenoma benign
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anogenital warts
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Basal cell carcinoma
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6219 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign ear neoplasm
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm of skin
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bowen's disease
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon adenoma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Dysplastic naevus
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Fibroma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Fibrous histiocytoma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Large intestine benign neoplasm
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lipoma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant melanoma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant melanoma in situ
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Melanocytic naevus
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Meningioma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nasopharyngeal neoplasm benign
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasm malignant
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasm skin
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pleomorphic adenoma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pyogenic granuloma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Seborrhoeic keratosis
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Skin cancer
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Skin papilloma
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6071 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of skin
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Amnesia
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Aphonia
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Balance disorder
|
0.07%
4/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6071 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Burning sensation
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Carotid artery stenosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Carpal tunnel syndrome
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Cerebrovascular accident
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Cerebrovascular disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Cervical radiculopathy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Cervicobrachial syndrome
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6071 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Cognitive disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Convulsions local
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Cubital tunnel syndrome
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Dementia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Diabetic neuropathy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Disturbance in attention
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Dizziness
|
1.2%
70/5784 • Number of events 78 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.59%
34/5734 • Number of events 35 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.3%
78/6071 • Number of events 80 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.96%
60/6219 • Number of events 64 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.5%
24/1573 • Number of events 25 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.0%
15/1464 • Number of events 15 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
1/59 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Dizziness postural
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Dysaesthesia
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Dysgeusia
|
0.09%
5/5784 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Epilepsy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Essential tremor
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Facial spasm
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Head discomfort
|
0.09%
5/5784 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6071 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Headache
|
8.2%
475/5784 • Number of events 669 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
3.6%
205/5734 • Number of events 275 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
5.4%
329/6071 • Number of events 403 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
2.6%
160/6219 • Number of events 212 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
3.9%
61/1573 • Number of events 70 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
2.0%
30/1464 • Number of events 36 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
1/59 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Hemiparesis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Hyperaesthesia
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Hypersomnia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Hypoaesthesia
|
0.10%
6/5784 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.16%
9/5734 • Number of events 11 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.20%
12/6071 • Number of events 12 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.11%
7/6219 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.20%
3/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
1/59 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Hypogeusia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Hypotonia
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Intercostal neuralgia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Lethargy
|
0.16%
9/5784 • Number of events 10 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/5734 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.20%
12/6071 • Number of events 12 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.32%
5/1573 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Loss of consciousness
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Memory impairment
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Migraine
|
0.14%
8/5784 • Number of events 15 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6071 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6219 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Motor dysfunction
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Muscle contractions involuntary
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Nerve compression
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Nervous system disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Neuralgia
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Neuropathy peripheral
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Paraesthesia
|
0.22%
13/5784 • Number of events 13 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.09%
5/5734 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.15%
9/6071 • Number of events 9 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Parkinson's disease
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Parkinsonism
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Petit mal epilepsy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Polyneuropathy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Poor quality sleep
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Presyncope
|
0.05%
3/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Radicular pain
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Radiculitis brachial
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Radiculopathy
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Restless legs syndrome
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Sciatica
|
0.10%
6/5784 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/5734 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.18%
11/6071 • Number of events 11 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.32%
20/6219 • Number of events 20 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
1/59 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Seizure
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Senile dementia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Sensory disturbance
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Sensory loss
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Sinus headache
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/5734 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Somnolence
|
0.22%
13/5784 • Number of events 17 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.28%
17/6071 • Number of events 20 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6219 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.32%
5/1573 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.20%
3/1464 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Spinal claudication
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Stupor
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Syncope
|
0.07%
4/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6071 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Tension headache
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Transient global amnesia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Transient ischaemic attack
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Tremor
|
0.07%
4/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.27%
4/1464 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Trigeminal neuralgia
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Nervous system disorders
Visual field defect
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Abnormal dreams
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Acute stress disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Affective disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Agitation
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Agoraphobia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Alcoholism
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Anxiety
|
0.22%
13/5784 • Number of events 13 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
8/6071 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.18%
11/6219 • Number of events 11 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.25%
4/1573 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.41%
6/1464 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Anxiety disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Aversion
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Confusional state
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Depressed mood
|
0.02%
1/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Depression
|
0.07%
4/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.12%
7/5734 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.15%
9/6071 • Number of events 9 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.16%
10/6219 • Number of events 11 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.25%
4/1573 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.41%
6/1464 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Depressive symptom
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Disorientation
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Dysphemia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Dysphoria
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Dysthymic disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Emotional disorder
|
0.02%
1/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Emotional distress
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Hallucination
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Hallucination, visual
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Insomnia
|
0.59%
34/5784 • Number of events 36 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.33%
19/5734 • Number of events 23 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.48%
29/6071 • Number of events 31 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.23%
14/6219 • Number of events 14 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.57%
9/1573 • Number of events 9 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.20%
3/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Irritability
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Libido decreased
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Listless
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Major depression
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Mental status changes
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Middle insomnia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Nervousness
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Nightmare
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Obsessive thoughts
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Panic attack
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Psychosomatic disease
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Restlessness
|
0.09%
5/5784 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Schizophrenia, paranoid type
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Sleep disorder
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Stress
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Tension
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Psychiatric disorders
Tic
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Bladder pain
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Bladder spasm
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Calculus bladder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Calculus ureteric
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Chromaturia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Chronic kidney disease
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Cystitis interstitial
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Dysuria
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Haematuria
|
0.09%
5/5784 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6219 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Hypertonic bladder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Incontinence
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Micturition disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Micturition urgency
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Nephritis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Nephrolithiasis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Nephropathy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Nocturia
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Pollakiuria
|
0.09%
5/5784 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6071 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Polyuria
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Renal colic
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Renal cyst
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Renal failure
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Renal pain
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Urethral stenosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Urge incontinence
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Urinary hesitation
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Urinary incontinence
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Urinary tract disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Renal and urinary disorders
Urine odour abnormal
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Atrophic vulvovaginitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Balanoposthitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Benign prostatic hyperplasia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
8/5734 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.12%
7/6071 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
8/6219 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Breast cyst
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Breast discomfort
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Breast enlargement
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Breast mass
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Breast pain
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Breast swelling
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Breast tenderness
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Cervical cyst
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Cervical polyp
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Cystocele
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Dysfunctional uterine bleeding
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Dysmenorrhoea
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Endometrial hyperplasia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Erectile dysfunction
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Genital discomfort
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Genital tract inflammation
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Genital ulceration
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Male sexual dysfunction
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Menopausal symptoms
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Menorrhagia
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Nipple disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Organic erectile dysfunction
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Pelvic pain
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Penile pain
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Postmenopausal haemorrhage
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Prostate induration
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Prostatic disorder
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Prostatism
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Prostatitis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Prostatomegaly
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Pruritus genital
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Rectocele
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Scrotal cyst
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Scrotal swelling
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Testicular mass
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Testicular pain
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Testis discomfort
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Uterine prolapse
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Vaginal erosion
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Vaginal haemorrhage
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Vaginal inflammation
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Vulvovaginal dryness
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Reproductive system and breast disorders
Vulvovaginal pruritus
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Asthma
|
0.07%
4/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
9/6219 • Number of events 9 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Atelectasis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Bronchial irritation
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Bronchiectasis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Bronchitis chronic
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
1/59 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Bronchospasm
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Catarrh
|
0.05%
3/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
|
0.07%
4/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6071 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.32%
5/1573 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.20%
3/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
1.2%
70/5784 • Number of events 74 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.1%
64/5734 • Number of events 66 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
88/6071 • Number of events 92 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.5%
96/6219 • Number of events 103 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.1%
18/1573 • Number of events 18 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.5%
22/1464 • Number of events 23 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
2.8%
2/72 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Dry throat
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Dysphonia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6219 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.12%
7/5784 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
8/6071 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.18%
11/6219 • Number of events 11 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.34%
5/1464 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea exertional
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Emphysema
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.12%
7/5784 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.09%
5/5734 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6071 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6219 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.48%
7/1464 • Number of events 12 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Increased upper airway secretion
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Increased viscosity of bronchial secretion
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Laryngeal oedema
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Laryngitis allergic
|
0.02%
1/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Lower respiratory tract congestion
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Lung disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Lung infiltration
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
0.10%
6/5784 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.21%
12/5734 • Number of events 16 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.18%
11/6071 • Number of events 11 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.11%
7/6219 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal discomfort
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal dryness
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal obstruction
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal polyps
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal pruritus
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal discomfort
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
1.4%
81/5784 • Number of events 84 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.1%
64/5734 • Number of events 69 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.91%
55/6071 • Number of events 56 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.90%
56/6219 • Number of events 59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.25%
4/1573 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.82%
12/1464 • Number of events 12 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Paranasal sinus discomfort
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Pharyngeal erythema
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural adhesion
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Pleurisy
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Pleuritic pain
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Productive cough
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/5734 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6219 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary mass
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Rales
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory disorder
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory tract congestion
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinalgia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinitis allergic
|
0.09%
5/5784 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/5734 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
9/6219 • Number of events 9 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.34%
5/1464 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinitis hypertrophic
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinorrhoea
|
0.33%
19/5784 • Number of events 23 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
11/5734 • Number of events 13 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.28%
17/6071 • Number of events 19 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.23%
14/6219 • Number of events 14 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Sinus congestion
|
0.07%
4/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Sinus disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Sleep apnoea syndrome
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Sneezing
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6071 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Snoring
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Sputum discoloured
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Sputum increased
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Throat irritation
|
0.03%
2/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Throat tightness
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Tonsillar disorder
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Upper respiratory tract inflammation
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Upper-airway cough syndrome
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Vasomotor rhinitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Vocal cord thickening
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Respiratory, thoracic and mediastinal disorders
Wheezing
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
1/59 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Acne
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Actinic keratosis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Alopecia
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Alopecia areata
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Angioedema
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Blister
|
0.10%
6/5784 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Cold sweat
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Decubitus ulcer
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Dermal cyst
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Dermatitis
|
0.09%
5/5784 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.09%
5/5734 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.21%
13/6219 • Number of events 13 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.32%
5/1573 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
1/59 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Dermatitis allergic
|
0.07%
4/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6071 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6219 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Dermatitis atopic
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Dermatitis contact
|
0.03%
2/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/5734 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.12%
7/6071 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
4/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Dermatitis exfoliative
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Dermatosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Diabetic foot
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Drug eruption
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Dry skin
|
0.05%
3/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Dyshidrotic eczema
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Ecchymosis
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Eczema
|
0.22%
13/5784 • Number of events 13 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.40%
23/5734 • Number of events 24 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.41%
25/6071 • Number of events 26 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.39%
24/6219 • Number of events 25 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.51%
8/1573 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.48%
7/1464 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Eczema asteatotic
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Erythema
|
0.36%
21/5784 • Number of events 22 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.12%
7/5734 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.33%
20/6071 • Number of events 20 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.23%
14/6219 • Number of events 15 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Erythema nodosum
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Hand dermatitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Hyperhidrosis
|
0.28%
16/5784 • Number of events 16 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/5734 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.16%
10/6071 • Number of events 10 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
8/6219 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Hyperkeratosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.08%
5/6071 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Hypersensitivity vasculitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Hypohidrosis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Idiopathic urticaria
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Ingrowing nail
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Lichen planus
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Lichen sclerosus
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Miliaria
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Nail growth abnormal
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Neurodermatitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Night sweats
|
0.09%
5/5784 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Onychalgia
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Onychoclasis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Onycholysis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Onychomadesis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Pain of skin
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Papule
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/5734 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Petechiae
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Photosensitivity reaction
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Pityriasis rosea
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Precancerous skin lesion
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Prurigo
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
0.64%
37/5784 • Number of events 38 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.61%
35/5734 • Number of events 36 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.74%
45/6071 • Number of events 48 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.90%
56/6219 • Number of events 64 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.5%
23/1573 • Number of events 24 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.89%
13/1464 • Number of events 13 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
1/59 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Pruritus generalised
|
0.07%
4/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.12%
7/5734 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
9/6219 • Number of events 9 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.32%
5/1573 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Psoriasis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.78%
45/5784 • Number of events 46 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.70%
40/5734 • Number of events 43 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.69%
42/6071 • Number of events 44 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.0%
63/6219 • Number of events 74 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.1%
18/1573 • Number of events 20 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.61%
9/1464 • Number of events 10 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Rash erythematous
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Rash generalised
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Rash macular
|
0.05%
3/5784 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.12%
7/5734 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Rash papular
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Rash pruritic
|
0.07%
4/5784 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/5734 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
9/6219 • Number of events 10 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Rosacea
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Seborrhoea
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Seborrhoeic dermatitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Senile pruritus
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Skin burning sensation
|
0.02%
1/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Skin discolouration
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Skin disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Skin exfoliation
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Skin fissures
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Skin irritation
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Skin lesion
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Skin plaque
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Skin striae
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Skin swelling
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Skin ulcer
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Skin warm
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Solar dermatitis
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Stasis dermatitis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Urticaria
|
0.19%
11/5784 • Number of events 11 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/5734 • Number of events 6 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.15%
9/6071 • Number of events 9 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.21%
13/6219 • Number of events 14 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.19%
3/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Skin and subcutaneous tissue disorders
Xeroderma
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Social circumstances
Occupational physical problem
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Abdominal operation
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Cataract operation
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Coronary arterial stent insertion
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Dental implantation
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Endodontic procedure
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Hip arthroplasty
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Meniscus operation
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Mouth cyst excision
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Shoulder operation
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Skin lesion excision
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Skin neoplasm excision
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Tooth extraction
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Umbilical hernia repair
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Vasectomy
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Angiopathy
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Aortic aneurysm
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Aortic stenosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Arteriosclerosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Behcet's syndrome
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Blood pressure fluctuation
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Blood pressure inadequately controlled
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6219 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Deep vein thrombosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Essential hypertension
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Flushing
|
0.12%
7/5784 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
8/6071 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Haematoma
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Haemorrhage
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Hot flush
|
0.09%
5/5784 • Number of events 5 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6071 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Hyperaemia
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Hypertension
|
0.43%
25/5784 • Number of events 26 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.52%
30/5734 • Number of events 30 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.59%
36/6071 • Number of events 37 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.66%
41/6219 • Number of events 41 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.51%
8/1573 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.2%
18/1464 • Number of events 19 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.7%
1/59 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
1.4%
1/72 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Hypertensive crisis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/5734 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.10%
6/6219 • Number of events 8 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.13%
2/1573 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Hypotension
|
0.03%
2/5784 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.12%
7/6071 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.11%
7/6219 • Number of events 7 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Intra-abdominal haematoma
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Ischaemia
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Labile blood pressure
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Lymphoedema
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Orthostatic hypotension
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Peripheral arterial occlusive disease
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Peripheral coldness
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
4/6071 • Number of events 4 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Peripheral vascular disorder
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/6071 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Peripheral venous disease
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.05%
3/6219 • Number of events 3 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Phlebitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.14%
2/1464 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Raynaud's phenomenon
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Temporal arteritis
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Thrombophlebitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.03%
2/5734 • Number of events 2 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.06%
1/1573 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Thrombophlebitis superficial
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/5734 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Thrombosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Varicose vein
|
0.02%
1/5784 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6071 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Vascular pain
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Vasculitis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.02%
1/6219 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1464 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
|
Surgical and medical procedures
Venous thrombosis
|
0.00%
0/5784 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/5734 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6071 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/6219 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/1573 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.07%
1/1464 • Number of events 1 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/59 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
0.00%
0/72 • Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).
Note that due to the retrospective observational nature of this study, new safety data was not collected in Zoster-064; the safety data presented here was originally collected as part of the Zoster-006 and Zoster-022 studies.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial
- Publication restrictions are in place
Restriction type: OTHER